[go: up one dir, main page]

ES2162823T3 - Inmunoglobulinas desprovistas de cadenas ligeras. - Google Patents

Inmunoglobulinas desprovistas de cadenas ligeras.

Info

Publication number
ES2162823T3
ES2162823T3 ES93919098T ES93919098T ES2162823T3 ES 2162823 T3 ES2162823 T3 ES 2162823T3 ES 93919098 T ES93919098 T ES 93919098T ES 93919098 T ES93919098 T ES 93919098T ES 2162823 T3 ES2162823 T3 ES 2162823T3
Authority
ES
Spain
Prior art keywords
desprovistas
immunoglobulins
light chains
chains
cadulasula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93919098T
Other languages
English (en)
Other versions
ES2162823T5 (es
Inventor
Cecile Casterman
Raymond Hamers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vrije Universiteit Brussel VUB
Universite Libre de Bruxelles ULB
Original Assignee
Vrije Universiteit Brussel VUB
Universite Libre de Bruxelles ULB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26132410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2162823(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP92402326A external-priority patent/EP0584421A1/en
Application filed by Vrije Universiteit Brussel VUB, Universite Libre de Bruxelles ULB filed Critical Vrije Universiteit Brussel VUB
Publication of ES2162823T3 publication Critical patent/ES2162823T3/es
Application granted granted Critical
Publication of ES2162823T5 publication Critical patent/ES2162823T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

EL INVENTO SE REFIERE A INMUNOGLOBULINA AISLADA CARACTERIZADA EN QUE COMPRENDEN DOS CADENAS DE POLIPEPTIDOS PESADOS SUFICIENTES PARA LA FORMACION DE UN LUGAR DE ENLACE ANTIGEN COMPLETO O LUGARES DE ENLACE DE ANTIGENO DIVERSO, ESTANDO ADEMAS ESTA INMUNOGLOBULINA DESPROVISTA DE CADENAS POLIPEPTIDAS LIGERAS.
ES93919098T 1992-08-21 1993-08-18 Inmunoglobulinas desprovistas de cadenas ligeras. Expired - Lifetime ES2162823T5 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP92402326A EP0584421A1 (en) 1992-08-21 1992-08-21 Immunoglobulins devoid of light chains
EP92402326 1992-08-21
EP93401310 1993-05-21
EP93401310 1993-05-21

Publications (2)

Publication Number Publication Date
ES2162823T3 true ES2162823T3 (es) 2002-01-16
ES2162823T5 ES2162823T5 (es) 2010-08-09

Family

ID=26132410

Family Applications (5)

Application Number Title Priority Date Filing Date
ES05008358T Expired - Lifetime ES2338791T3 (es) 1992-08-21 1993-08-18 Inmunoglobulinas desprovistas de cadenas ligeras.
ES05020889T Expired - Lifetime ES2325541T3 (es) 1992-08-21 1993-08-18 Inmunoglobulinas desprovistas de cadenas ligeras.
ES93919098T Expired - Lifetime ES2162823T5 (es) 1992-08-21 1993-08-18 Inmunoglobulinas desprovistas de cadenas ligeras.
ES00127968T Expired - Lifetime ES2322324T3 (es) 1992-08-21 1993-08-18 Inmumoglobulinas desprovistas de cadenas ligeras.
ES04077639T Expired - Lifetime ES2338321T3 (es) 1992-08-21 1993-08-18 Inmunoglobulinas desprovistas de cadenas ligeras.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES05008358T Expired - Lifetime ES2338791T3 (es) 1992-08-21 1993-08-18 Inmunoglobulinas desprovistas de cadenas ligeras.
ES05020889T Expired - Lifetime ES2325541T3 (es) 1992-08-21 1993-08-18 Inmunoglobulinas desprovistas de cadenas ligeras.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES00127968T Expired - Lifetime ES2322324T3 (es) 1992-08-21 1993-08-18 Inmumoglobulinas desprovistas de cadenas ligeras.
ES04077639T Expired - Lifetime ES2338321T3 (es) 1992-08-21 1993-08-18 Inmunoglobulinas desprovistas de cadenas ligeras.

Country Status (13)

Country Link
US (5) US5840526A (es)
EP (6) EP1087013B1 (es)
JP (4) JP3444885B2 (es)
AT (5) ATE427968T1 (es)
AU (1) AU701578B2 (es)
CA (1) CA2142331C (es)
DE (6) DE69334258D1 (es)
DK (5) DK1498427T3 (es)
ES (5) ES2338791T3 (es)
FI (3) FI115462B (es)
GR (1) GR3037024T3 (es)
PT (5) PT656946E (es)
WO (1) WO1994004678A1 (es)

Families Citing this family (1318)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6765087B1 (en) * 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
CA2258518C (en) * 1996-06-27 2011-11-22 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
US20040248201A1 (en) * 1996-06-27 2004-12-09 Serge Muyldermans Recognition molecules interacting specifically with the active site or cleft of a target molecule
IL129363A (en) * 1996-10-10 2003-02-12 Neose Technologies Inc Carbohydrate purification using ultrafiltration, reverse osmosis and nanofiltration
US20030228310A1 (en) * 1996-12-23 2003-12-11 Advanced Biotherapy, Inc. Treatment of skin diseases
BR9907241A (pt) * 1998-01-26 2000-10-17 Unilever Nv Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo
DE69920897T2 (de) * 1998-04-28 2005-10-13 Smithkline Beecham Corp. Monoklonale antikörper mit verringerter immunisierungsfähigkeit
ID30380A (id) 1999-04-22 2001-11-29 Unilever Nv Penghambatan infeksi virus menggunakan protein pengikat antigen bervalensi tunggal
US6924359B1 (en) * 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
BR0012711A (pt) 1999-07-27 2002-04-09 Unilever Nv Composição detergente enzimática, e, processos para aumentar a atividade e / ou a estabilidade de uma oxidorredutase dependente de co-fator e para branquear manchas presentes em tecidos
DE60019309T2 (de) * 1999-09-16 2005-09-22 Unilever Plc Abgabesystem für ein mittel gegen schuppen
US6479280B1 (en) * 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
EP1088892A1 (en) * 1999-09-24 2001-04-04 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
EP1242460B1 (en) 1999-11-29 2006-10-18 Unilever Plc Immobilisation of proteins using a polypeptide segment
EP1118669A3 (en) * 1999-12-17 2001-08-29 Unilever Plc Production of camelid antibodies in plants
ATE428733T1 (de) 2000-03-14 2009-05-15 Unilever Nv Variabele domänen der schweren kette eines antikörpers gegen menschliche ernährungslipasen und deren verwendungen
US6696620B2 (en) * 2000-05-02 2004-02-24 Epicyte Pharmaceutical, Inc. Immunoglobulin binding protein arrays in eukaryotic cells
CA2380443C (en) * 2000-05-26 2013-03-12 Ginette Dubuc Single-domain antigen-binding antibody fragments derived from llama antibodies
WO2002057445A1 (en) 2000-05-26 2002-07-25 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
JP4368196B2 (ja) * 2000-11-17 2009-11-18 ユニバーシティー オブ ロチェスター 真核細胞において免疫グロブリン分子を製造および同定するインビトロにおける方法
US20060064782A1 (en) * 2000-12-18 2006-03-23 Conopco, Inc. Production of antibodies
CA2431485A1 (en) 2000-12-19 2002-06-27 Unilever Plc Stabilization of antibodies or fragments thereof
WO2002051870A2 (en) * 2000-12-22 2002-07-04 GRAD, Carole Legal Representative of KAPLAN, Howard Phage display libraries of human vh fragments
WO2002080982A2 (en) 2001-01-12 2002-10-17 Chiron Corporation Nucleic acid mucosal immunization
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20050069538A1 (en) * 2003-09-18 2005-03-31 Gregorio Aversa Therapeutic binding molecules
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US6861056B2 (en) * 2001-06-05 2005-03-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US20040086508A1 (en) * 2001-06-05 2004-05-06 Advanced Biotherapy, Inc. Treatment of organ transplant rejection
US20050152902A1 (en) * 2001-06-05 2005-07-14 Advanced Biotherapy, Inc. Treatment of diabetic retinopathy
US20040062768A1 (en) * 2001-06-05 2004-04-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
JP4323317B2 (ja) * 2001-12-21 2009-09-02 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） 可変領域配列のクローニング方法
EP1461085A2 (en) * 2002-01-03 2004-09-29 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Immunoconjugates useful for treatment of tumours
WO2003057728A1 (en) 2002-01-10 2003-07-17 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw A novel splice variant of myd88 and uses thereof
AU2002333502A1 (en) 2002-02-10 2003-09-04 Apoxis Sa Fusion constructs containing active sections of tnf ligands
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
DE60305919T2 (de) * 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
PT2269656E (pt) 2002-07-15 2014-12-02 Univ Texas Anticorpos selecionados e peptídeos de duramicina que se ligam a fosfolipídios aniônicos e aminofosfolipídios e seus usos no tratamento de infecções virais e câncer
AU2003251238A1 (en) 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
JP4459810B2 (ja) 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
GB0219720D0 (en) * 2002-08-23 2002-10-02 Univ Aberdeen Polypeptide
US20040052790A1 (en) * 2002-09-18 2004-03-18 Advanced Biotherapy, Inc. Treatment of schizophrenia
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
EP1558650A2 (en) 2002-11-08 2005-08-03 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
EP1437764A1 (en) * 2003-01-10 2004-07-14 S.O.I. Tec Silicon on Insulator Technologies S.A. A compliant substrate for a heteroepitaxy, a heteroepitaxial structure and a method for fabricating a compliant substrate
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
CA2529819A1 (en) 2003-06-30 2004-09-23 Domantis Limited Pegylated single domain antibodies
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
EP3095793B1 (en) 2003-07-28 2020-03-25 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
WO2005014795A2 (en) 2003-08-08 2005-02-17 Genenews Inc. Osteoarthritis biomarkers and uses thereof
US20060127404A1 (en) * 2003-09-30 2006-06-15 Chichi Huang Hinge core mimetibodies, compositions, methods and uses
CN1878568A (zh) 2003-11-05 2006-12-13 盘林京有限公司 Cdim结合抗体的增强的b细胞细胞毒性
EP2251357A1 (en) 2003-11-07 2010-11-17 Ablynx N.V. Camelidae single domain antibodies VHH directed against epidermal growth factor receptor and uses therefor
DK1697399T3 (en) 2003-12-12 2017-03-06 Government Of The United States Of America As Repr By The Secr Of The Dept Of Health And Human Servi Human cytotoxic t lymphocyte epitope and its agonist epitope from the non-variable number of muc-1 tandem repeat sequences
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005105984A2 (en) * 2004-04-12 2005-11-10 The Trustees Of The University Of Pennsylvania Culture conditions and growth factors affecting fate determination, self-renewal and expansion of mouse spermatogonial stem cells
JP2008501337A (ja) * 2004-06-04 2008-01-24 ジェネンコー・インターナショナル・インク 抗体重鎖を用いたスクリーニング法
US20050276807A1 (en) * 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
US20050276806A1 (en) * 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of autism
GB2416768A (en) * 2004-07-22 2006-02-08 Univ Erasmus Heavy chain immunoglobulin complexes
LT2311874T (lt) 2004-07-22 2017-11-27 Erasmus University Medical Center Rotterdam Rišančiosios molekulės
US20060177445A1 (en) * 2004-08-16 2006-08-10 Boris Skurkovich Treatment of inflammatory skin diseases
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
CN101724071A (zh) 2004-10-08 2010-06-09 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
US7462454B2 (en) * 2004-10-12 2008-12-09 Advanced Biotherapy, Inc. Treatment of herpes
US20080107601A1 (en) * 2004-10-13 2008-05-08 Ablynx N.V. Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease
JP2008518023A (ja) 2004-10-27 2008-05-29 メディミューン，インコーポレーテッド 同族抗原に対する親和性を改変することによる抗体特異性の調節
JP4829897B2 (ja) 2005-01-14 2011-12-07 アブリンクス ナームローゼ フェンノートシャップ 血小板減少及び／又はフォンビルブラント因子（ｖＷＦ）と血小板との間の自発的相互作用によって特徴づけられる疾患及び障害の異なる形態を区別する方法及びアッセイ
EP1844073A1 (en) * 2005-01-31 2007-10-17 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
EP2520669A3 (en) 2005-02-07 2013-02-27 GeneNews Inc. Mild osteoathritis biomarkers and uses thereof
ES2852549T3 (es) 2005-02-09 2021-09-13 Sarepta Therapeutics Inc Composición antisentido para tratamiento de la atrofia muscular
US8349328B2 (en) * 2005-03-11 2013-01-08 Syngenta Crop Protection Llc Rodent control agents comprising antibodies that binds to rodent specific peptide epitopes
EP3144675A1 (en) 2005-04-28 2017-03-22 Ventana Medical Systems, Inc. Enzymes conjugated to antibodies via a peg heterobifuctional linker
AU2006239154A1 (en) * 2005-04-28 2006-11-02 Ventana Medical Systems, Inc Nanoparticle conjugates
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
PL2444424T3 (pl) 2005-05-20 2019-01-31 Ablynx N.V. Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
PT1912675E (pt) 2005-07-25 2014-05-09 Emergent Product Dev Seattle Moléculas de ligaçao especificas para cd37 e especificas para cd20
ME02705B (me) 2005-08-31 2017-10-20 Merck Sharp & Dohme Inženjerisana anti-il-23 antitela
EP2116258A1 (en) 2005-09-01 2009-11-11 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
US20090233357A1 (en) * 2005-09-27 2009-09-17 Abedelnasser Abulrob Targeted Delivery of Compounds Using Multimerization Technology
EP1941275B1 (en) 2005-09-29 2013-07-24 Medimmune, Inc. Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
US7526409B2 (en) * 2005-10-07 2009-04-28 Oracle International Corporation Automatic performance statistical comparison between two periods
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US8239136B2 (en) 2005-10-21 2012-08-07 Genenews Inc. Method, computer system and computer-readable medium for determining a probability of colorectal cancer in a test subject
GB0522460D0 (en) * 2005-11-03 2005-12-14 Prendergast Patrick T Composition and method for the treatment of avian influenza
DK2963011T3 (en) 2005-11-23 2018-08-06 Ventana Med Syst Inc MOLECULAR CONJUGATE
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
AU2007209201A1 (en) * 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
US7504106B2 (en) * 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
US20100226920A1 (en) * 2006-03-27 2010-09-09 Ablynx N.V. Medical delivery device for therapeutic proteins based on single domain antibodies
US20080070268A1 (en) * 2006-04-21 2008-03-20 Wyeth Differential expression profiling analysis of cell culture phenotypes and the uses thereof
CN101437945A (zh) 2006-05-02 2009-05-20 阿克托杰尼斯有限公司 肥胖相关肽的微生物肠内递送
MX380352B (es) 2006-06-12 2025-03-12 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
US9056906B2 (en) 2006-06-14 2015-06-16 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
PT2029173T (pt) 2006-06-26 2016-11-02 Macrogenics Inc Anticorpos específicos fc rib e seus métodos de uso
CN101541950A (zh) 2006-07-13 2009-09-23 惠氏公司 糖蛋白的产生
WO2008027338A2 (en) 2006-08-28 2008-03-06 Kyowa Hakko Kirin Co., Limited Antagonistic human light-specific human monoclonal antibodies
CA3154415A1 (en) 2006-10-10 2008-04-17 Regenesance B.V. Anti-sense oligonucleotide for use in facilitating axonal regeneration
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
DK3564674T3 (da) 2006-11-01 2021-10-18 Ventana Med Syst Inc Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til fremstilling og anvendelse deraf
AU2007316597B2 (en) 2006-11-07 2013-01-31 Katholieke Universiteit Leuven, K. U. Leuven R & D Diagnosis and treatment of T-cell acute lymphoblastic leukemia
CA2670471A1 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
US20080267949A1 (en) * 2006-12-05 2008-10-30 Ablynx N.V. Peptides capable of binding to serum proteins
AU2007334499B2 (en) 2006-12-14 2014-04-24 Merck Sharp & Dohme Corp. Engineered anti-TSLP antibody
US9156914B2 (en) 2006-12-19 2015-10-13 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
EP2115004A2 (en) 2006-12-19 2009-11-11 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
AU2008219216A1 (en) * 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
CN101663320A (zh) 2007-02-23 2010-03-03 先灵公司 工程改造的抗IL-23p19抗体
SI2426144T1 (sl) 2007-02-23 2019-02-28 Merck Sharp & Dohme Corp. Umetno proizvedena anti-IL23P19 antitelesa
CN101668531B (zh) 2007-02-28 2014-05-07 默沙东公司 用于治疗免疫病症的联合治疗
US8119133B2 (en) 2007-02-28 2012-02-21 Schering Corporation Engineered anti-IL-23R antibodies
HUE026403T2 (en) * 2007-03-02 2016-06-28 Wyeth Llc Use of copper and glutamate in cell culture to produce polypeptides
US20100129437A1 (en) 2007-03-23 2010-05-27 Bbb Holding B.V. Targeted intracellular delivery of antiviral agents
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
EP2164868B1 (en) 2007-05-04 2015-03-25 Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA Engineered rabbit antibody variable domains and uses thereof
WO2008143878A1 (en) 2007-05-14 2008-11-27 Medimmune, Llc Methods of reducing eosinophil levels
JP2010528285A (ja) 2007-05-23 2010-08-19 ベンタナ・メデイカル・システムズ・インコーポレーテツド 免疫組織化学およびｉｎｓｉｔｕハイブリダーゼーションのためのポリマー担体
EP2336329B8 (en) 2007-06-01 2012-11-21 Omt, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenis human idiotype antibodies
WO2008157299A2 (en) * 2007-06-15 2008-12-24 Wyeth Differential expression profiling analysis of cell culture phenotypes and uses thereof
CA2691940C (en) 2007-07-03 2018-03-06 Joost Alexander Kolkman Methods for providing improved immunoglobulin sequences
WO2009012181A2 (en) 2007-07-13 2009-01-22 Ventana Medical Systems, Inc. Method of identifying diagnostic reagents
WO2009011572A1 (en) 2007-07-13 2009-01-22 Bac Ip B.V. Single-domain antigen-binding proteins that bind mammalian igg
US20090042253A1 (en) 2007-08-09 2009-02-12 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors
CA2700714C (en) 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
MX2010004327A (es) 2007-10-22 2010-05-13 Schering Corp Anticuerpos anti-vegf completamente humanos y metodos de uso.
JP5514399B2 (ja) * 2007-11-02 2014-06-04 国立大学法人 岡山大学 無機硫黄化合物加水分解酵素の製造方法
WO2009056634A2 (en) 2007-11-02 2009-05-07 Novartis Ag Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
CA2960659C (en) 2007-11-09 2021-07-13 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
CA2706200A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Immunoglobulin constructs comprising multiple single variable domains and an fc portion
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
WO2009086215A2 (en) * 2007-12-21 2009-07-09 Wyeth Pathway analysis of cell culture phenotypes and uses thereof
CA3052615A1 (en) 2008-01-31 2009-08-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Engineered antibody constant domain molecules
EP2247616A2 (en) 2008-03-05 2010-11-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making and uses thereof
US9908943B2 (en) 2008-04-03 2018-03-06 Vib Vzw Single domain antibodies capable of modulating BACE activity
GB0809069D0 (en) 2008-05-19 2008-06-25 Univ Leuven Kath Gene signatures
US8568717B2 (en) 2008-04-03 2013-10-29 Vib Vzw Single domain antibodies capable of modulating BACE activity
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
RS51975B (sr) 2008-04-11 2012-02-29 Emergent Product Development Seattle Llc. Cd37 imunoterapeutski proizvod i njegova kombinacija sa bifunkcionalnim hemoterapeutskim sredstvom
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
WO2009133208A1 (en) 2008-05-02 2009-11-05 Novartis Ag Improved fibronectin-based binding molecules and uses thereof
CN102099373A (zh) 2008-05-22 2011-06-15 百时美施贵宝公司 基于纤连蛋白的多价支架结构域蛋白
EP2300799B1 (en) 2008-06-05 2015-11-25 Ventana Medical Systems, Inc. Method for histochemical processessing and use of a composition for histochemical processing
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
JP5675608B2 (ja) 2008-07-18 2015-02-25 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ２８結合のための一価組成物および使用方法
WO2010010119A1 (en) 2008-07-22 2010-01-28 Ablynx Nv Amino acid sequences directed against multitarget scavenger receptors and polypeptides
BRPI0916668B1 (pt) 2008-08-05 2021-12-28 Novartis Ag Anticorpo monoclonal isolado, composição farmacêutica, ácido nucleico isolado e vetor
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
EP2344180A2 (en) 2008-09-23 2011-07-20 Wyeth LLC Methods for predicting production of activating signals by cross-linked binding proteins
KR101593285B1 (ko) 2008-10-29 2016-02-11 아블린쓰 엔.브이. 단일 도메인 항원 결합 분자의 제형
WO2010056550A1 (en) 2008-10-29 2010-05-20 Wyeth Llc Methods for purification of single domain antigen binding molecules
CN102257131A (zh) 2008-12-19 2011-11-23 先灵公司 用于哺乳动物细胞培养的给料添加剂及使用方法
CN102257003B (zh) 2008-12-19 2017-04-05 埃博灵克斯股份有限公司 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫
DK2387583T3 (en) 2009-01-14 2019-01-14 Ablynx Nv PULMONAL ADMINISTRATION OF VARIABLE IMMUNGLOBULIN SINGLE DOMAINS AND CONSTRUCTIONS THEREOF.
US20100189919A1 (en) * 2009-01-27 2010-07-29 Xerox Corporation Imaging System And Process Using Monoclonal Antibodies
CA2750520C (en) 2009-02-04 2017-12-05 Molecular Innovations Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
US10005830B2 (en) 2009-03-05 2018-06-26 Ablynx N.V. Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
EP2230515B1 (en) 2009-03-16 2014-12-17 Agilent Technologies, Inc. Passivation of surfaces after ligand coupling
US9586180B2 (en) 2009-03-24 2017-03-07 Wyeth Llc Membrane evaporation for generating highly concentrated protein therapeutics
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
KR20130119990A (ko) 2009-04-10 2013-11-01 아블린쓰 엔.브이. Ｉｌ－６ｒ에 대한 개선된 아미노산 서열 및 ｉｌ－６ｒ 관련 질환 및 질병의 치료를 위한 그를 포함하는 폴리펩티드
SG174273A1 (en) 2009-04-27 2011-10-28 Novartis Ag Compositions and methods for increasing muscle growth
MX2011011338A (es) 2009-04-27 2012-04-19 Novartis Ag Composiciones y metodos de uso para anticuerpos terapeuticos especificos para la subunidad beta1 del receptor de il-12.
US9464138B2 (en) 2009-04-30 2016-10-11 Ablynx N.V. Method for the production of domain antibodies
WO2011019423A2 (en) 2009-05-20 2011-02-17 Schering Corporation Modulation of pilr receptors to treat microbial infections
CA2764398A1 (en) 2009-06-05 2010-12-09 Erik Depla Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
JP2012531212A (ja) 2009-07-03 2012-12-10 アビペップ ピーティーワイ リミテッド イムノコンジュゲート及びその作製方法
US9150640B2 (en) 2009-07-10 2015-10-06 Ablynx N.V. Method for the production of variable domains
US20120230918A1 (en) 2009-07-28 2012-09-13 Hoffmann-La-Roche Inc. Non-invasive in vivo optical imaging method
CA2769473A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
WO2011018421A1 (en) 2009-08-10 2011-02-17 Morphosys Ag Novel screening strategies for the identification of binders
EP2805731B1 (en) 2009-09-03 2018-10-31 Ablynx N.V. Stable formulations of polypeptides and uses thereof
AU2010290989B2 (en) 2009-09-03 2016-05-19 Cancer Research Technology Limited CLEC14A inhibitors
SG178991A1 (en) 2009-09-03 2012-04-27 Schering Corp Anti-gitr antibodies
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
UY32917A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moléculas de unión a dll-4
UY32920A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
WO2011042398A1 (en) 2009-10-09 2011-04-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
WO2011045079A1 (en) 2009-10-15 2011-04-21 Intercell Ag Hepatitis b virus specific human antibodies
WO2011049449A1 (en) 2009-10-22 2011-04-28 University Of Twente Vhh for application in tissue repair, organ regeneration, organ replacement and tissue engineering
CA3031851C (en) 2009-10-23 2020-07-07 Amgen British Columbia Anti-gcc antibody molecules and related compositions and methods
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051333A1 (en) 2009-10-30 2011-05-05 Novartis Ag Universal fibronectin type iii bottom-side binding domain libraries
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011056772A1 (en) 2009-11-04 2011-05-12 Schering Corporation Engineered anti-tslp antibody
WO2011054893A2 (en) 2009-11-05 2011-05-12 Novartis Ag Biomarkers predictive of progression of fibrosis
EP2507262A1 (en) 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
SMT201900251T1 (it) 2009-12-10 2019-07-11 Regeneron Pharma Topi che producono anticorpi della catena pesante
WO2011072266A2 (en) 2009-12-11 2011-06-16 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
EP2513145B1 (en) 2009-12-14 2018-01-24 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
US8691227B2 (en) 2009-12-17 2014-04-08 Merck Sharp & Dohme Corp. Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
EP2516462B1 (en) 2009-12-23 2015-05-06 Avipep Pty Ltd Immuno-conjugates and methods for producing them
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
CN102781959A (zh) 2010-02-05 2012-11-14 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
AU2011214465A1 (en) 2010-02-10 2012-08-30 Novartis Ag Methods and compounds for muscle growth
ES2931330T3 (es) 2010-02-11 2022-12-28 Ablynx Nv Métodos y composiciones para la preparación de aerosoles
EP2533814A2 (en) 2010-02-11 2012-12-19 Ablynx N.V. Delivery of immunoglobulin variable domains and constructs thereof
ES2606012T3 (es) 2010-02-26 2017-03-17 Ventana Medical Systems, Inc. Hibridación in situ con sondas PolyTag
EP2542579A1 (en) 2010-03-03 2013-01-09 Boehringer Ingelheim International GmbH Biparatopic abeta binding polypeptides
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
US20130041349A1 (en) 2010-03-26 2013-02-14 Westfaelische Wilhelms-Universitaet Muenster Substitute therapy for glucocorticoids
WO2013174537A1 (en) 2012-05-24 2013-11-28 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
EP2555614B1 (en) 2010-04-06 2018-11-14 Agrosavfe N.V. Specific delivery of agrochemicals
GB201105584D0 (en) 2011-04-01 2011-05-18 Imp Innovations Ltd Cancer methods
CA2796087A1 (en) 2010-04-20 2011-10-27 Ventana Medical Systems, Inc. Two-color chromogenic in situ hybridization
AU2011248625B2 (en) 2010-04-26 2017-01-05 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
WO2011139799A2 (en) 2010-04-27 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
EP2563911B1 (en) 2010-04-28 2021-07-21 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
JP5991963B2 (ja) 2010-04-29 2016-09-14 エータイアー ファーマ， インコーポレイテッド バリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
AU2011248490B2 (en) 2010-04-29 2016-11-10 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
NZ629829A (en) 2010-04-30 2015-11-27 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
WO2011140132A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
JP6008841B2 (ja) 2010-05-03 2016-10-19 エータイアー ファーマ， インコーポレイテッド メチオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
AU2011248355B2 (en) 2010-05-03 2017-01-19 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Arginyl-tRNA synthetases
WO2011140267A2 (en) 2010-05-04 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
EP3138915A1 (en) 2010-05-04 2017-03-08 The Brigham and Women's Hospital, Inc. Detection and treatment of fibrosis
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
WO2011138392A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
PE20130206A1 (es) 2010-05-06 2013-02-28 Novartis Ag Anticuerpos multivalentes antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
KR20130036012A (ko) 2010-05-07 2013-04-09 에프. 호프만-라 로슈 아게 생체외 세포의 검출을 위한 진단 방법
CA2799197C (en) 2010-05-14 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
RU2012149227A (ru) 2010-05-20 2014-06-27 Аблинкс Нв Биологические материалы, относящиеся к her3
JP6046607B2 (ja) 2010-05-27 2016-12-21 エータイアー ファーマ， インコーポレイテッド グルタミニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
MX2012014975A (es) 2010-06-22 2013-03-12 Univ Colorado Regents Anticuerpos al fragmento c3d de componente 3 de complemento.
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
EP2588443A2 (en) 2010-07-02 2013-05-08 Ventana Medical Systems, Inc. Hapten conjugates for target detection
EP2588865A1 (en) 2010-07-02 2013-05-08 Vib Vzw The role of fragile x mental retardation gene and protein in cancer metastasis
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
CA2805572A1 (en) 2010-07-16 2012-01-19 Martin Hegen Modified single domain antigen binding molecules and uses thereof
GB201014715D0 (en) 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
GB201012845D0 (en) 2010-07-30 2010-09-15 Vib Vzw Inhibition of dicer function for treatment of cancer
CA2807282A1 (en) 2010-08-02 2012-02-09 Regeneron Pharamaceuticals, Inc. Mice that make binding proteins comprising vl domains
DK2606055T3 (en) 2010-08-16 2015-09-07 Ventana Med Syst Inc Chromogenic detection substrates and methods for use in detection assays and kits
ME02637B (me) 2010-08-20 2017-06-20 Novartis Ag Antitela za receptor 3 faktora rasta epiderma (her3)
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
CA2808539C (en) 2010-08-25 2021-05-25 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
ES2634547T3 (es) 2010-08-26 2017-09-28 Agrosavfe N.V. Composiciones para el tratamiento de semillas
US20130224226A1 (en) 2010-08-26 2013-08-29 Agrosavfe N.V. Insect binding antibodies
US20120225081A1 (en) 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
CN103154037A (zh) 2010-10-05 2013-06-12 诺瓦提斯公司 抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
HUE069364T2 (hu) 2010-10-29 2025-03-28 Ablynx Nv Eljárás immunglobulin variábilis egydomének elõállítására
GB201018602D0 (en) 2010-11-04 2010-12-22 Vib Vzw MMP8 inactivating antigen binding proteins
JP6224456B2 (ja) 2010-11-05 2017-11-01 モルフォテック、インク． 葉酸受容体アルファ発現癌の診断および予後マーカーとしての葉酸受容体アルファ
ES2723775T3 (es) 2010-11-08 2019-09-02 Ablynx Nv Polipéptidos que se unen a CXCR2
EP2656079A2 (en) 2010-12-20 2013-10-30 Universiteit Gent Crystal structure of flt3 ligand-receptor complex
EP2658869B1 (en) 2010-12-30 2019-06-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigen binding formats for use in therapeutic treatments or diagnostic assays
CA2817374C (en) 2010-12-30 2018-10-16 Ventana Medical Systems, Inc. Enhanced deposition of chromogens utilizing pyrimidine analogs
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
CN103459427B (zh) 2011-02-01 2018-03-30 Bac Ip私人有限公司 针对人IgG抗体的CH1结构域中表位的抗原结合蛋白
CA2826453A1 (en) 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Use of an anti-cd200 antibody for prolonging the survival of allografts
WO2012120004A1 (en) 2011-03-07 2012-09-13 F. Hoffmann-La Roche Ag In vivo selection of therapeutically active antibodies
WO2012119999A1 (en) 2011-03-07 2012-09-13 F. Hoffmann-La Roche Ag Means and methods for in vivo testing of therapeutic antibodies
EP2686016B1 (en) 2011-03-14 2019-05-01 Cellmid Limited Antibody recognizing n-domain of midkine
CN103534359B (zh) 2011-03-14 2016-07-06 文塔纳医疗系统公司 分析染色体易位的方法及其系统
DK2691415T3 (en) 2011-03-28 2018-10-29 Ablynx Nv PROCEDURE FOR PREPARING SOLID FORMULATIONS CONTAINING VARIABLE SINGLE DOMAINS OF IMMUNOGLOBULIN
CN103917560B (zh) 2011-03-28 2017-05-24 埃博灵克斯股份有限公司 双特异性抗‑cxcr7免疫球蛋白单可变结构域
WO2012131053A1 (en) 2011-03-30 2012-10-04 Ablynx Nv Methods of treating immune disorders with single domain antibodies against tnf-alpha
EA201301090A1 (ru) 2011-03-30 2014-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Антидоты антикоагулянтов
AU2012236479B2 (en) 2011-03-31 2016-10-20 Merck Sharp & Dohme Llc Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
ES2669310T3 (es) 2011-04-20 2018-05-24 Medimmune, Llc Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
WO2012152823A1 (en) 2011-05-09 2012-11-15 Ablynx Nv Method for the production of immunoglobulin single variable domains
CN107903325B (zh) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
BR112013030298A2 (pt) 2011-05-27 2017-12-12 Ablynx Nv inibição da reabsorção óssea com peptídeos que se ligam ao rankl
WO2012166906A1 (en) 2011-05-31 2012-12-06 Massachusetts Institute Of Technology Cell-directed synthesis of multifunctional nanopatterns and nanomaterials
CN103649123B (zh) 2011-06-13 2017-05-24 Csl有限公司 抗g‑csfr抗体及其用途
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
CA2839834A1 (en) 2011-06-21 2012-12-27 Vib Vzw Binding domains directed against gpcr:g protein complexes and uses derived thereof
JP2014525736A (ja) 2011-06-23 2014-10-02 アブリンクス エン．ヴェー． ＩｇＥに対する免疫グロブリン単一可変ドメイン
EP4218933A1 (en) 2011-06-23 2023-08-02 Ablynx NV Serum albumin binding proteins
WO2013006437A1 (en) 2011-07-01 2013-01-10 Novartis Ag Method for treating metabolic disorders
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
WO2013010955A1 (en) 2011-07-15 2013-01-24 Morphosys Ag Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
MY167125A (en) 2011-08-17 2018-08-13 Glaxo Group Ltd Modified proteins and peptides
WO2013033073A1 (en) 2011-08-31 2013-03-07 Ventana Medical Systems, Inc. Expression of ets related gene (erg) and phosphatase and tensin homolog (pten) correlates with prostate cancer capsular penetration
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
WO2013036130A1 (en) 2011-09-09 2013-03-14 Universiteit Utrecht Holding B.V. Broadly neutralizing vhh against hiv-1
CN103945689B (zh) 2011-09-19 2016-10-19 科马布有限公司 免疫球蛋白基因多样性的操纵及多抗体治疗剂
US20140235492A1 (en) 2011-09-20 2014-08-21 Institut National De La Sante Et De La Recherche Medicate (Inserm) Methods for preparing single domain antibody microarrays
US10138302B2 (en) 2011-09-23 2018-11-27 Ablynx N.V. Methods for treating rheumatoid arthritis by administering interleukin-6 receptor antibodies
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
JP6219287B2 (ja) 2011-09-30 2017-10-25 アブリンクス エン．ヴェー． ｃ−Ｍｅｔに関連する生物学的物質
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
EP3653222A1 (en) 2011-10-14 2020-05-20 Novartis AG Antibodies and methods for wnt pathway-related diseases
WO2013059206A2 (en) 2011-10-17 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Monospecific and bispecific human monoclonal antibodies targeting insulin-growth factor ii (igf-ii)
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
JP2015504413A (ja) 2011-10-28 2015-02-12 パトリス リミテッド Ｐａｔ−ｌｍ１エピトープおよびそれを使用するための方法
BR112014011304B1 (pt) 2011-11-11 2022-03-03 UCB Biopharma SRL Anticorpos de ligação com albumina e fragmentos de ligação dos mesmos, proteína de fusão de anticorpo bi-específico, polinucleotídeo, célula hospedeira, processo de produção de anticorpo ou fragamento do mesmo, formulação farmacêutica e uso
WO2013079606A1 (en) 2011-12-01 2013-06-06 Ventana Medical Systems, Inc. Automated dual stain of mirna and protein targets
EP2785741A1 (en) 2011-12-02 2014-10-08 Cancer Research Technology Limited Antibodies against hgf - receptor and uses
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
KR20140103135A (ko) 2011-12-05 2014-08-25 노파르티스 아게 Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
ES2758433T3 (es) 2011-12-05 2020-05-05 Novartis Ag Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3)
AP2014007761A0 (en) 2011-12-21 2014-07-31 Novartis Ag Compositions and methods for antibodies targeting factor P
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
WO2013108126A2 (en) 2012-01-16 2013-07-25 University Of Oslo Methyltransferases and uses thereof
PT2804878T (pt) 2012-01-20 2018-11-29 Genzyme Corp Anticorpos anti-cxcr3
US20150301068A1 (en) 2012-01-30 2015-10-22 Vib Vzw Means and method for diagnosis and treatment of alzheimer's disease
WO2013121042A1 (en) 2012-02-16 2013-08-22 Vib Vzw PP2A SUBUNITS IN DNA REPAIR, THE PP2A B55α SUBUNIT AS NOVEL PHD2 INTERACTING PROTEIN, AND IMPLICATIONS FOR CANCER
EP4050027A3 (en) 2012-02-27 2022-11-30 Ablynx N.V. Cx3cr1-binding polypeptides
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
WO2013148498A1 (en) 2012-03-27 2013-10-03 Ventana Medical Systems, Inc. Signaling conjugates and methods of use
MX350248B (es) 2012-03-30 2017-08-31 Boehringer Ingelheim Int Moleculas de union a ang2.
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
EP2687595B1 (en) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII
CN110256559B (zh) 2012-07-25 2023-05-26 塞尔德克斯医疗公司 抗kit抗体及其用途
EP2877211A4 (en) 2012-07-25 2016-02-10 Salk Inst For Biological Studi CONTROL OF INTERACTION BETWEEN TAM LIGANDS AND LIPID MEMBRANES WITH EXPOSED PHOSPHATIDYL SERININE
US9605074B2 (en) 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
CN109364250A (zh) 2012-10-09 2019-02-22 比奥根Ma公司 联合治疗及用于治疗脱髓鞘病症的用途
MX359950B (es) 2012-11-20 2018-10-17 Novartis Ag Casete de expresión optimizado para expresar un polipéptido con un alto rendimiento.
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
CA2893767C (en) 2012-12-05 2022-11-08 Novartis Ag Compositions and methods for antibodies targeting epo
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
EP2931030B2 (en) 2012-12-14 2024-01-17 OmniAb, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
US20140186350A1 (en) 2012-12-18 2014-07-03 Novartis Ag Compositions and methods for long acting molecules
SG11201504764SA (en) 2012-12-19 2015-07-30 Amplimmune Inc Anti-human b7-h4 antibodies and their uses
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
JP6359031B2 (ja) 2012-12-21 2018-07-18 メディミューン，エルエルシー 抗ｈ７ｃｒ抗体
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
PT2951201T (pt) 2013-01-30 2018-01-09 Univ Brussel Vrije Novos polipéptidos quiméricos para rastreamento e fins de descoberta de fármacos
WO2014120916A1 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Pegylated domain antibodies monovalent for cd28 binding and methods of use
WO2014122183A1 (en) 2013-02-05 2014-08-14 Vib Vzw Muscarinic acetylcholine receptor binding agents and uses thereof
AU2014214530B2 (en) 2013-02-07 2014-10-16 Csl Limited IL-11R binding proteins and uses thereof
AP2015008584A0 (en) 2013-02-08 2015-07-31 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
WO2015198217A2 (en) 2013-02-08 2015-12-30 Novartis Ag Compositions and methods for long-acting antibodies targeting il-17
EP3444278A1 (en) 2013-02-26 2019-02-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
AU2014223824B2 (en) 2013-02-28 2020-02-27 Albert Einstein College Of Medicine, Inc. Tuberculosis biomarkers and uses thereof
AU2013381730B2 (en) 2013-03-12 2017-07-27 Ventana Medical Systems, Inc. Digitally enhanced microscopy for multiplexed histology
EP3689904A1 (en) 2013-03-13 2020-08-05 Prothena Biosciences Limited Tau immunotherapy
CN105246916A (zh) 2013-03-14 2016-01-13 诺华股份有限公司 针对notch 3的抗体
US9745368B2 (en) 2013-03-15 2017-08-29 The Trustees Of The University Of Pennsylvania Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
WO2014144292A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
JP6499090B2 (ja) 2013-03-15 2019-04-10 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ 心血管疾患において使用するための抗マクロファージマンノース受容体単一可変ドメイン
HK1220205A1 (zh) 2013-03-15 2017-04-28 Celgene Corporation 修饰的t淋巴细胞
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US10233249B2 (en) 2013-03-19 2019-03-19 Beijing Shenogen Pharma Group Ltd. Antibodies and methods for treating estrogen receptor-associated diseases
US20160145325A1 (en) 2013-04-29 2016-05-26 Agrosavfe N.V. Agrochemical compositions comprising antibodies binding to sphingolipids
EP3583950A1 (en) 2013-05-09 2019-12-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
SG11201509618QA (en) 2013-05-24 2015-12-30 Medimmune Llc Anti-b7-h5 antibodies and their uses
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
NZ714765A (en) 2013-06-06 2021-12-24 Pf Medicament Anti-c10orf54 antibodies and uses thereof
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
US9562101B2 (en) 2013-06-21 2017-02-07 Novartis Ag Lectin-like oxidized LDL receptor 1 antibodies and methods of use
JP6474797B2 (ja) 2013-06-27 2019-02-27 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル インターロイキン１５（ｉｌ−１５）アンタゴニスト並びに自己免疫疾患及び炎症性疾患の処置のためのその使用
EP3016973A1 (en) 2013-07-05 2016-05-11 INSERM - Institut National de la Santé et de la Recherche Médicale Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
US9951131B2 (en) 2013-07-12 2018-04-24 Prothena Biosciences Limited Antibodies that recognize IAPP
KR102192596B1 (ko) 2013-08-07 2020-12-18 알렉시온 파마슈티칼스, 인코포레이티드 비정형적 용혈성 요독증후군 (ahus) 바이오마커 단백질
US20160200818A1 (en) 2013-08-14 2016-07-14 Novartis Ag Methods of treating Sporadic Inclusion Body Myositis
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
CA2931357C (en) 2013-11-28 2022-07-12 Csl Limited Method of treating nephropathy
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
CA2932465C (en) 2013-12-18 2023-08-22 Csl Limited Methods of treating wounds in a diabetic subject
WO2015090230A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
EP4566623A3 (en) 2013-12-20 2025-08-20 Intervet International B.V. Caninized antibodies
JP6793902B2 (ja) 2013-12-20 2020-12-02 ノバルティス アーゲー 調節可能キメラ抗原受容体
WO2015100409A2 (en) 2013-12-26 2015-07-02 Tufts University Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
EP3099707B1 (en) 2014-01-30 2021-12-29 Vib Vzw Opioid receptor binding agents and uses thereof
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
JP6764348B2 (ja) 2014-02-11 2020-09-30 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子およびその使用
JP2017506640A (ja) 2014-02-14 2017-03-09 セントローズ， エルエルシー 細胞外標的化薬物共役体
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
CA2936962C (en) 2014-03-14 2024-03-05 Novartis Ag Antibody molecules to lag-3 and uses thereof
WO2015142661A1 (en) 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
ES2939760T3 (es) 2014-03-15 2023-04-26 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico para antígenos
SG11201607015VA (en) 2014-03-21 2016-09-29 Regeneron Pharma V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
WO2015155694A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
MX382565B (es) 2014-04-25 2025-03-13 2Seventy Bio Inc Receptores de antigenos quimericos del promotor mnd.
KR102161927B1 (ko) 2014-04-25 2020-10-06 블루버드 바이오, 인코포레이티드. 양자 세포 치료제를 제조하는 개선된 방법
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
KR20250099289A (ko) 2014-05-16 2025-07-01 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
SG10201810124PA (en) 2014-05-16 2018-12-28 Ablynx Nv Improved immunoglobulin variable domains
SG10201912986PA (en) 2014-05-28 2020-02-27 Agenus Inc Anti-gitr antibodies and methods of use thereof
ES2846811T3 (es) 2014-06-06 2021-07-29 Bluebird Bio Inc Composiciones de células T mejoradas
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
EP3160990A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
WO2015198240A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
EP3722316A1 (en) 2014-07-21 2020-10-14 Novartis AG Treatment of cancer using a cd33 chimeric antigen receptor
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
JP7054622B2 (ja) 2014-07-21 2022-04-14 ノバルティス アーゲー ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
US10641779B2 (en) 2014-07-22 2020-05-05 Vib Vzw Methods to select for agents that stabilize protein complexes
SG10201900455YA (en) 2014-07-24 2019-02-27 Bluebird Bio Inc Bcma chimeric antigen receptors
EP3180037A1 (en) 2014-07-29 2017-06-21 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
FI3174559T3 (fi) 2014-07-29 2023-01-13 Radioleimattuja vasta-ainefragmentteja käytettäväksi syövän ehkäisyssä ja/tai hoidossa
ES2781175T3 (es) 2014-07-31 2020-08-31 Novartis Ag Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
MA40512A (fr) 2014-08-07 2021-03-24 Novartis Ag Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
US10851149B2 (en) 2014-08-14 2020-12-01 The Trustees Of The University Of Pennsylvania Treatment of cancer using GFR α-4 chimeric antigen receptor
JO3664B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme أجسام مضادة لـ tigit
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
ES2791248T3 (es) 2014-08-19 2020-11-03 Novartis Ag Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
CA2960824A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
US10577417B2 (en) 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EP3662903A3 (en) 2014-10-03 2020-10-14 Novartis AG Combination therapies
KR102510540B1 (ko) 2014-10-03 2023-03-16 나노틱스 엘엘씨 가용성 생물분자의 생물학적 활성을 억제하기 위한 조성물 및 방법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016055656A1 (en) 2014-10-10 2016-04-14 Ablynx N.V. Methods of treating rsv infections
DK3204095T3 (da) 2014-10-10 2019-07-15 Ablynx Nv Inhalationsindretning til anvendelse i aerosolbehandling af luftsvejssygdomme
CA2964367C (en) 2014-10-14 2024-01-30 Novartis Ag Antibody molecules to pd-l1 and uses thereof
WO2016061632A1 (en) 2014-10-23 2016-04-28 La Trobe University Fn14-binding proteins and uses thereof
BR112017009330A2 (pt) 2014-11-05 2017-12-19 Agrosavfe N V planta transgênica que compreende um polinucleotídeo que codifica um domínio variável de anticorpo de cadeia pesada
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
WO2016094602A1 (en) 2014-12-10 2016-06-16 Tufts University Vhh based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
TN2017000246A1 (en) 2014-12-11 2018-10-19 Pf Medicament Anti-c10orf54 antibodies and uses thereof
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
WO2016094304A2 (en) 2014-12-12 2016-06-16 Bluebird Bio, Inc. Bcma chimeric antigen receptors
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
WO2016094962A1 (en) 2014-12-19 2016-06-23 Monash University Il-21 antibodies
ES2772348T3 (es) 2014-12-19 2020-07-07 Ablynx Nv Dímeros de Nanobody con uniones cisteína
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
JP7211703B2 (ja) 2014-12-22 2023-01-24 ザ ロックフェラー ユニバーシティー 抗ｍｅｒｔｋアゴニスト抗体及びその使用
IL253149B2 (en) 2014-12-29 2023-11-01 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
MX391051B (es) 2014-12-30 2025-03-21 Celgene Corp Anticuerpos anti-cd47 y usos de los mismos.
EP3240801B1 (en) 2014-12-31 2021-01-20 Checkmate Pharmaceuticals, Inc. Combination tumor immunotherapy
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016124558A1 (en) 2015-02-03 2016-08-11 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
WO2016124568A1 (en) 2015-02-03 2016-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-rho gtpase conformational single domain antibodies and uses thereof
US20180022781A1 (en) 2015-02-13 2018-01-25 Inserm (Institut National De La Sante Et De La Recherche Medicale) Polypeptides for engineering integrase chimeric proteins and their use in gene therapy
WO2016138160A1 (en) 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
CN114504652A (zh) 2015-03-03 2022-05-17 科马布有限公司 抗体、用途和方法
RU2758113C2 (ru) 2015-03-17 2021-10-26 Мемориал Слоан-Кеттеринг Кэнсер Сентер Антитела к muc16 и их применение
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
WO2016149678A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
US20180074077A1 (en) 2015-03-25 2018-03-15 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of factor d of the alternative complement pathway
US20180087087A1 (en) 2015-03-25 2018-03-29 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of c3 and c5 convertase of the alternative complement pathway
CA2981103A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
KR102789821B1 (ko) 2015-03-31 2025-04-02 소리소 파마슈티컬스 인크. 프로테아제-절단가능 링커를 갖는 펩티드 구조물
DK4089113T3 (da) 2015-03-31 2024-02-05 Sorriso Pharmaceuticals Inc Polypeptider
CN107683291B (zh) 2015-04-02 2021-11-19 英特维特国际股份有限公司 针对犬白介素-4受体α的抗体
WO2016156570A1 (en) 2015-04-02 2016-10-06 Ablynx N.V. Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity
WO2016164580A1 (en) 2015-04-07 2016-10-13 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
ES2841437T3 (es) 2015-04-13 2021-07-08 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de enfermedades hemorrágicas
US9778265B2 (en) 2015-04-16 2017-10-03 The United States Of America, As Represented By The Secretary Of The Navy Charged peptide appendage to facilitate oriented protein covalent immobilization
US20180112006A1 (en) 2015-04-17 2018-04-26 The General Hospital Corporation Agents, systems and methods for treating cancer
WO2016168595A1 (en) 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
US12128069B2 (en) 2015-04-23 2024-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CN115109158A (zh) 2015-05-07 2022-09-27 阿吉纳斯公司 抗ox40抗体及其使用方法
EP3736287A1 (en) 2015-05-11 2020-11-11 The Johns Hopkins University Autoimmune antibodies for use in inhibiting cancer cell growth
LT3611192T (lt) 2015-05-13 2025-06-25 Ablynx N.V. T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu
PL3294319T3 (pl) 2015-05-13 2024-10-07 Ablynx Nv Polipeptydy rekrutujące komórki t na podstawie reaktywności cd3
CN107849148B (zh) 2015-05-21 2023-09-19 哈普恩治疗公司 三特异性结合蛋白质及使用方法
CN115925961A (zh) 2015-05-28 2023-04-07 生物辐射实验室股份有限公司 亲和配体及其相关方法
US10144779B2 (en) 2015-05-29 2018-12-04 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
AU2016273028B2 (en) 2015-06-05 2019-02-14 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor
EP3307777A4 (en) 2015-06-11 2019-02-13 Wuxi Biologics (Shanghai) Co. Ltd. NOVEL ANTI-PD-L1 ANTIBODIES
EP3314260B1 (en) 2015-06-24 2021-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for detecting protein-protein interactions
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
EP3325020B1 (en) 2015-07-17 2022-01-12 Vrije Universiteit Brussel Radiolabelled antibody fragments for use in treating cancer
AR105433A1 (es) 2015-07-21 2017-10-04 Novartis Ag Métodos para mejorar la eficacia y expansión de las células inmunes
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
US20190008983A1 (en) 2015-07-31 2019-01-10 James R. Prudent Extracellular drug conjugates targeting cd20
IL257105B (en) 2015-07-31 2022-09-01 Univ Minnesota Modified cells and methods of therapy
CA2994516A1 (en) 2015-08-03 2017-02-09 Novartis Ag Methods of treating fgf21-associated disorders
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
JP7008014B2 (ja) 2015-08-07 2022-02-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 有効な部位特異的バイオコンジュゲーションのためのトランスグルタミンタグ
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
HRP20241381T1 (hr) 2015-08-11 2024-12-20 WuXi Biologics Ireland Limited Nova anti-pd-1 protutijela
CA2996893A1 (en) 2015-08-31 2017-03-09 Bluebird Bio, Inc. Anti-sialyl tn chimeric antigen receptors
KR20220131277A (ko) 2015-09-01 2022-09-27 아게누스 인코포레이티드 항-pd-1 항체 및 이를 이용하는 방법
WO2017040930A2 (en) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
EP3347377B1 (en) 2015-09-09 2021-02-17 Novartis AG Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
WO2017042701A1 (en) 2015-09-09 2017-03-16 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
BR112018005573A2 (pt) 2015-09-21 2019-01-22 Aptevo Research And Development Llc ?polipeptídeos de ligação a cd3?
US11203634B2 (en) 2015-10-07 2021-12-21 Alexion Pharmaceuticals, Inc. Methods of treating age-related macular degeneration in a patient comprising administering an anti-C5a antibody
WO2017062835A2 (en) 2015-10-09 2017-04-13 Sarepta Therapeutics, Inc. Compositions and methods for treating duchenne muscular dystrophy and related disorders
CN105238759B (zh) * 2015-10-14 2019-05-24 吉日木图 抗驼乳重链IgG3单克隆抗体、含有所述单克隆抗体的试纸及其应用
ES2981535T3 (es) 2015-11-10 2024-10-09 Visterra Inc Conjugados de molécula de anticuerpo-fármaco que se unen específicamente al lipopolisacárido y usos de los mismos
NO2768984T3 (es) 2015-11-12 2018-06-09
WO2017081190A1 (en) 2015-11-13 2017-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
CA3132021C (en) 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
EA038179B1 (ru) 2015-11-18 2021-07-20 Мерк Шарп И Доум Корп. Ctla4-связывающие вещества
PL3380522T3 (pl) 2015-11-25 2024-03-25 Visterra, Inc. Cząsteczki przeciwciał wobec april i ich zastosowania
BR112018010802A2 (pt) 2015-11-27 2018-11-27 Ablynx Nv polipeptídeos que inibem cd40l
CN108368167B (zh) 2015-11-27 2023-09-05 杰特有限公司 Cd131结合蛋白及其应用
CN108289943B (zh) 2015-12-04 2023-06-20 勃林格殷格翰国际有限公司 在肿瘤细胞中拮抗wnt信号传递的双互补位多肽
US11479755B2 (en) 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
WO2017097889A1 (en) 2015-12-10 2017-06-15 Katholieke Universiteit Leuven Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device
BR112018012352A2 (pt) 2015-12-16 2018-12-11 Merck Sharp & Dohme Corp. anticorpos anti-lag3 e fragmentos de ligação ao antígeno
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
KR20180094977A (ko) 2015-12-17 2018-08-24 노파르티스 아게 c-Met 억제제와 PD-1에 대한 항체 분자의 조합물 및 그의 용도
EP4541807A3 (en) 2015-12-18 2025-09-24 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
CA3008102A1 (en) 2015-12-18 2017-06-22 Novartis Ag Antibodies targeting cd32b and methods of use thereof
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
EP3393504B1 (en) 2015-12-22 2025-09-24 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
CA3009852A1 (en) 2015-12-28 2017-07-06 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP3998281A1 (en) 2016-02-05 2022-05-18 Orionis Biosciences BV Cd8 binding agents
US11180546B2 (en) 2016-02-17 2021-11-23 Novartis Ag TGFbeta 2 antibodies
WO2017149515A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
CN109069573B (zh) 2016-03-07 2022-04-05 弗拉芒区生物技术研究所 结合cd20的单结构域抗体
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
WO2017158396A1 (en) 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
US20190086392A1 (en) 2016-03-21 2019-03-21 Inserm (Institut National De La Sante Et De La Recherch Medicale) Methods for diagnosis and treatment of solar lentigo
JP7082604B2 (ja) 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
WO2017161976A1 (en) 2016-03-23 2017-09-28 Mabspace Biosciences (Suzhou) Co., Ltd Novel anti-pd-l1 antibodies
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
US11760803B2 (en) 2016-03-24 2023-09-19 Takeda Pharmaceutical Company Limited Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
WO2017165736A1 (en) 2016-03-25 2017-09-28 Visterra, Inc. Formulation of antibody molecules to dengue virus
WO2017176762A1 (en) 2016-04-06 2017-10-12 Nanotics, Llc Particles comprising subparticles or nucleic acid scaffolds
EP3442993B1 (en) 2016-04-13 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for the rapid detection of the escherichia coli o25b-st131 clone
CN109311963A (zh) 2016-04-14 2019-02-05 蓝鸟生物公司 救助嵌合抗原受体系统
US20170298119A1 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
EP3443096B1 (en) 2016-04-15 2023-03-01 Novartis AG Compositions and methods for selective expression of chimeric antigen receptors
EP3445393A4 (en) 2016-04-20 2020-08-05 Merck Sharp & Dohme Corp. CMV NEUTRALIZATION ANTIGEN BINDING PROTEINS
US11243214B2 (en) 2016-04-22 2022-02-08 Université Libre de Bruxelles Biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
WO2017182605A1 (en) 2016-04-22 2017-10-26 Université Libre de Bruxelles A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
US11312766B2 (en) 2016-04-27 2022-04-26 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof
WO2017191559A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
JP2019523213A (ja) 2016-05-02 2019-08-22 アブリンクス エン．ヴェー． Ｒｓｖ感染の処置
CA3023881A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Therapeutic targeting of non-cellular structures
KR20220103806A (ko) 2016-05-18 2022-07-22 베링거 인겔하임 인터내셔날 게엠베하 암 치료용 항-pd1 및 항-lag3 항체
LT3461261T (lt) 2016-05-20 2025-08-25 Harpoon Therapeutics, Inc. Vienos grandinės kintamo fragmento cd3 surišantys baltymai
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3463452A1 (en) 2016-05-24 2019-04-10 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
JP2019517473A (ja) 2016-05-27 2019-06-24 アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 難治性全身型重症筋無力症の処置のための方法
KR20230091191A (ko) 2016-05-27 2023-06-22 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
US11534496B2 (en) 2016-06-07 2022-12-27 The Brigham And Women's Hospital, Inc. Compositions and methods relating to T peripheral helper cells in autoantibody-associated conditions
JP7231411B2 (ja) 2016-06-15 2023-03-01 ノバルティス アーゲー 骨形成タンパク質６（ｂｍｐ６）の阻害剤を使用して疾患を処置する方法
WO2017223419A1 (en) 2016-06-24 2017-12-28 Ig Biosciences Corporation Prebiotic neutraceutical compositions and methods of treatment using the same
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
MA45602A (fr) 2016-07-08 2019-05-15 Staten Biotechnology B V Anticorps anti-apoc3 et leurs méthodes d'utilisation
MA45668A (fr) 2016-07-13 2019-05-22 Biogen Ma Inc Schémas posologiques d'antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation
CN110461315B (zh) 2016-07-15 2025-05-02 诺华股份有限公司 使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018017964A2 (en) 2016-07-21 2018-01-25 Emory University Ebola virus antibodies and binding agents derived therefrom
IL316970A (en) 2016-07-28 2025-01-01 Novartis Ag Combination therapies of chimeric antigen receptors and PD-1 inhibitors
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
KR20190036551A (ko) 2016-08-01 2019-04-04 노파르티스 아게 Pro-m2 대식세포 분자의 억제제를 병용하는, 키메라 항원 수용체를 이용한 암의 치료
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
JP7464389B2 (ja) 2016-08-02 2024-04-09 ビステラ， インコーポレイテッド 操作されたポリペプチドおよびその使用
JP2019528311A (ja) 2016-08-03 2019-10-10 ネクストキュア インコーポレイテッド Ｌａｉｒシグナル伝達を調節するための組成物及び方法
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
WO2018050833A1 (en) 2016-09-15 2018-03-22 Ablynx Nv Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
WO2018054241A1 (en) 2016-09-20 2018-03-29 Wuxi Biologics (Shanghai) Co., Ltd. Novel anti-pcsk9 antibodies
KR102644544B1 (ko) 2016-09-21 2024-03-11 넥스트큐어 인코포레이티드 Siglec-15를 위한 항체 및 이의 사용 방법
EP4360714A3 (en) 2016-09-21 2024-07-24 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
WO2018057955A1 (en) 2016-09-23 2018-03-29 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
CA3034105A1 (en) 2016-09-23 2018-03-29 Csl Limited Coagulation factor binding proteins and uses thereof
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions
WO2018067992A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
BR112019007369A2 (pt) 2016-10-11 2019-07-16 Agenus Inc anticorpos anti-lag-3 e métodos de uso dos mesmos
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
US20190276524A1 (en) 2016-10-12 2019-09-12 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
JP7181862B2 (ja) 2016-10-18 2022-12-01 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 腫瘍浸潤リンパ球および治療の方法
US11828683B2 (en) 2016-10-19 2023-11-28 Alexion Pharmaceuticals, Inc. Method of quantitating unbound C5a in a sample
ES2848206T3 (es) 2016-10-19 2021-08-05 Alexion Pharma Inc Un método de cuantificar C5 sin unir en una muestra
SMT202100555T1 (it) 2016-10-21 2021-11-12 Inst Nat Sante Rech Med Metodi per promuovere la risposta di cellule t
EP3532845A1 (en) 2016-10-27 2019-09-04 Alexion Pharmaceuticals, Inc. Assay for c5b-9 deposition in complement-associated disorders
US20190263926A1 (en) 2016-10-28 2019-08-29 Astute Medical, Inc. Use of Antibodies to TIMP-2 for the Improvement of Renal Function
WO2018078083A1 (en) 2016-10-28 2018-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating multiple myeloma
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN110022906A (zh) 2016-11-04 2019-07-16 蓝鸟生物公司 抗bcma car t细胞组合物
US11332521B2 (en) 2016-11-07 2022-05-17 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
IL266506B2 (en) 2016-11-16 2025-05-01 Ablynx Nv T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
IL309526B2 (en) 2016-11-17 2025-02-01 2Seventy Bio Inc TGFBeta signal converter
WO2018091720A1 (en) 2016-11-21 2018-05-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the prophylactic treatment of metastases
WO2018098354A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
CA3044729A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
WO2018102746A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
CA3046082A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Antibodies and methods of use thereof
MA50949B1 (fr) 2016-12-07 2023-12-29 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et leurs procédés d'utilisation
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112256A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
CA3046023A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
AU2017376807B2 (en) 2016-12-14 2024-07-18 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with an IL-12/IL-23 inhibitor released using an ingestible device
EP3554345A1 (en) 2016-12-14 2019-10-23 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
EP3554344A1 (en) 2016-12-14 2019-10-23 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
JP7150724B2 (ja) 2016-12-14 2022-10-11 ビオラ・セラピューティクス・インコーポレイテッド 消化管疾病のｔｎｆ阻害薬による治療
JP7150723B2 (ja) 2016-12-14 2022-10-11 ビオラ・セラピューティクス・インコーポレイテッド 消化管疾病のインテグリン阻害薬による治療
BR112019012062A2 (pt) 2016-12-14 2019-11-12 Progenity Inc tratamento de uma doença do trato gastrointestinal com um inibidor de jak e dispositivos
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
IL308980A (en) 2016-12-23 2024-01-01 Novartis Ag Antibodies against factor XI and methods of their use
WO2018119402A1 (en) 2016-12-23 2018-06-28 Visterra, Inc. Binding polypeptides and methods of making the same
US11613785B2 (en) 2017-01-09 2023-03-28 Onkosxcel Therapeutics, Llc Predictive and diagnostic methods for prostate cancer
WO2018136626A1 (en) 2017-01-18 2018-07-26 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
KR102777514B1 (ko) 2017-01-19 2025-03-06 옴니에이비 오퍼레이션스, 인코포레이티드 다중 중쇄 면역글로불린 유전자좌를 갖는 트랜스제닉 설치류 기원의 인간 항체
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
WO2018141753A1 (en) 2017-01-31 2018-08-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating squamous cell carcinomas
IL268346B2 (en) 2017-02-06 2024-08-01 Orionis Biosciences BV Targeted chimeric proteins and uses thereof
KR102572663B1 (ko) 2017-02-08 2023-09-01 노파르티스 아게 Fgf21 모방 항체 및 이의 용도
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
JP7186401B2 (ja) 2017-02-28 2022-12-09 フエー・イー・ベー・フエー・ゼツト・ウエー タンパク質の経口送達のための手段及び方法
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN
EP3589647A1 (en) 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
EP3943940A1 (en) 2017-03-14 2022-01-26 NanoTag Biotechnologies GmbH Target detection using a monovalent antibody
EP4095161A1 (en) 2017-03-15 2022-11-30 Tsinghua University Novel anti-trkb antibodies
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
IL269083B2 (en) 2017-03-24 2024-12-01 Novartis Ag Methods for preventing and treating heart disease
US20200330590A1 (en) 2017-03-27 2020-10-22 Celgene Corporation Methods and compositions for reduction of immunogenicity
EP3600416B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
CA3054156A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
EP3601531B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with live biotherapeutics
CA3054159A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
KR20200020662A (ko) 2017-04-03 2020-02-26 온콜로지, 인크. 면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
KR102629972B1 (ko) 2017-04-13 2024-01-29 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
EP3610264A1 (en) 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2018189403A1 (en) 2017-04-14 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancer
CA3058290A1 (en) 2017-04-18 2018-10-25 Universite Libre De Bruxelles Biomarkers and targets for proliferative diseases
US20200123238A1 (en) 2017-04-19 2020-04-23 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
JP2020517256A (ja) 2017-04-19 2020-06-18 エルスター セラピューティクス， インコーポレイテッド 多重特異性分子およびその使用
CN110506056A (zh) 2017-04-21 2019-11-26 斯塔滕生物技术有限公司 抗apoc3抗体和其使用方法
AU2018260545B2 (en) 2017-04-28 2023-11-23 Marengo Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3618863B1 (en) 2017-05-01 2023-07-26 Agenus Inc. Anti-tigit antibodies and methods of use thereof
CA3062238A1 (en) 2017-05-11 2018-11-15 Vib Vzw Glycosylation of variable immunoglobulin domains
EP3621648A4 (en) 2017-05-12 2021-01-20 Harpoon Therapeutics, Inc. TRISPECIFIC PROTEINS MSLN AND METHOD OF USE
CN113896792B (zh) 2017-05-12 2025-08-22 哈普恩治疗公司 间皮素结合蛋白质
JP7169298B2 (ja) 2017-05-12 2022-11-10 オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド ヒトアルファフェトタンパク質特異的ｔ細胞受容体およびその使用
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2018222587A1 (en) 2017-05-30 2018-12-06 The Regents Of The University Of California NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif)
PE20200610A1 (es) 2017-05-31 2020-03-10 Boehringer Ingelheim Int Polipeptidos que antagonizan la senalizacion wnt en celulas tumorales
WO2018222901A1 (en) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
CN110691790A (zh) 2017-06-02 2020-01-14 勃林格殷格翰国际有限公司 抗癌联合治疗
US12129308B2 (en) 2017-06-02 2024-10-29 Merck Patent Gmbh MMP13 binding immunoglobulins
EP3630818A1 (en) 2017-06-02 2020-04-08 Ablynx NV Aggrecan binding immunoglobulins
EP3630817A1 (en) 2017-06-02 2020-04-08 Merck Patent GmbH Polypeptides binding adamts5, mmp13 and aggrecan
KR102752550B1 (ko) 2017-06-02 2025-01-10 메르크 파텐트 게엠베하 Adamts 결합성 면역글로불린
EP3415010A1 (en) 2017-06-13 2018-12-19 Agrosavfe Nv Insect-controlling polypeptides and methods
GB201709379D0 (en) 2017-06-13 2017-07-26 Univ Leuven Kath Humanised ADAMTS13 binding antibodies
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
US20190062428A1 (en) 2017-06-19 2019-02-28 Surface Oncology, Inc. Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
MY204117A (en) 2017-06-22 2024-08-08 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
WO2019003165A1 (en) 2017-06-27 2019-01-03 Neuracle Science Co., Ltd. ANTI-FAM19A5 ANTIBODIES AND USES THEREOF
MX2019015738A (es) 2017-06-27 2020-02-20 Novartis Ag Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
WO2019005756A1 (en) 2017-06-28 2019-01-03 The Rockefeller University CONJUGATES AGONIST ANTIBODY ANTI-MERTK-MEDICINE
TW201906865A (zh) 2017-06-28 2019-02-16 瑞士商諾華公司 預防及治療尿失禁之方法
JP2020530307A (ja) 2017-06-30 2020-10-22 インティマ・バイオサイエンス，インコーポレーテッド 遺伝子治療のためのアデノ随伴ウイルスベクター
SG11201913137VA (en) 2017-07-11 2020-01-30 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
CN111201246B (zh) 2017-07-11 2023-10-27 亚力兄制药公司 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
WO2019012030A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
EP3655436B1 (en) 2017-07-19 2025-10-15 Vib Vzw Serum albumin binding agents
EP3431496A1 (en) 2017-07-19 2019-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti- isoasp7 amyloid beta antibodies and uses thereof
AU2018302283B2 (en) 2017-07-20 2025-07-10 Novartis Ag Dosage regimens of anti-LAG-3 antibodies and uses thereof
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra ANTI-NUCLEOLIN ANTIBODIES
US11174322B2 (en) 2017-07-24 2021-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat HCMV related diseases
CN116271012A (zh) 2017-07-27 2023-06-23 瑞颂医药公司 高浓度抗c5抗体制剂
JP2020529605A (ja) 2017-08-01 2020-10-08 コンパス セラピューティクス リミテッド ライアビリティ カンパニー 濾過およびクロマトグラフィ用ポッドならびにその使用方法
WO2019036363A1 (en) 2017-08-14 2019-02-21 Progenity Inc. TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH GLATIRAMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3684811A2 (en) 2017-08-17 2020-07-29 Massachusetts Institute of Technology Multiple specificity binders of cxc chemokines and uses thereof
EP3679070A1 (en) 2017-09-07 2020-07-15 Augusta University Research Institute, Inc. Antibodies to programmed cell death protein 1
IL273202B2 (en) 2017-09-11 2024-08-01 Univ Monash Binding proteins to the human thrombin receptor, par4
US20200268837A1 (en) 2017-09-20 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating autophagy
CA3074032A1 (en) 2017-10-02 2019-04-11 Visterra, Inc. Antibody molecules to cd138 and uses thereof
ES2759622T3 (es) 2017-10-02 2020-05-11 Certest Biotec S L Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
KR102425983B1 (ko) 2017-10-13 2022-07-29 하푼 테라퓨틱스, 인크. 삼중특이적 단백질 및 사용 방법
JP7395471B2 (ja) 2017-10-13 2023-12-11 オーセ イミュノセラピューティクス 改変抗ＳＩＲＰａ抗体及びその使用
US11466073B2 (en) 2017-10-18 2022-10-11 Csl Limited Human serum albumin variants and uses thereof
JP7422070B2 (ja) 2017-10-19 2024-01-25 デバイオファーム インターナショナル エス．エー． 癌の治療のための配合剤
CN111566124A (zh) 2017-10-25 2020-08-21 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
BR112020008182A2 (pt) 2017-10-26 2020-10-27 Alexion Pharmaceuticals, Inc. dosagem e administração de anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna (hpn) e síndrome hemolítica urêmica atípica (shua)
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
CA3076791A1 (en) 2017-10-31 2019-05-09 Vib Vzw Novel antigen-binding chimeric proteins and methods and uses thereof
MX2020004512A (es) 2017-10-31 2020-08-13 Anticuerpos anti apolipoproteina c-iii (anti-apoc3) y metodos de uso de los mismos.
US20190160102A1 (en) 2017-11-03 2019-05-30 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems for tumor growth inhibition
CA3081602A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
ES2939461T3 (es) 2017-11-29 2023-04-24 Csl Ltd Método para tratar o prevenir la lesión por isquemia-reperfusión
WO2019106126A1 (en) 2017-12-01 2019-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Mdm2 modulators for the diagnosis and treatment of liposarcoma
US12173316B2 (en) 2017-12-05 2024-12-24 Celyad S.A Compositions and methods for improving persistence of cells for adoptive transfer
JP2021505207A (ja) 2017-12-05 2021-02-18 セリアド エス．アー．Ｃｅｌｙａｄ Ｓ．Ａ． Ｎｋｇ２ｄベースの受容体を発現する免疫細胞のフラトリサイドの減少
JP7348899B2 (ja) 2017-12-08 2023-09-21 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性分子及びその使用
WO2019121872A1 (en) 2017-12-20 2019-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of liver cancer
WO2019129054A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
WO2019129137A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
WO2019129136A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
CN115925943A (zh) 2017-12-27 2023-04-07 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
JP7369127B2 (ja) 2017-12-28 2023-10-25 ナンジン レジェンド バイオテック カンパニー，リミテッド Ｔｉｇｉｔに対する単一ドメイン抗体及びその変異体
CN108218990B (zh) 2017-12-29 2021-03-02 南京优迈生物科技有限公司 分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
WO2019140116A2 (en) 2018-01-10 2019-07-18 Rubius Therapeutics, Inc. Amplifiable rnas for therapeutic cell systems
KR20250114571A (ko) 2018-01-15 2025-07-29 난징 레전드 바이오테크 씨오., 엘티디. Pd-1에 대한 단일-도메인 항체 및 이의 변이체
US10899823B2 (en) 2018-01-18 2021-01-26 California Institute Of Technology Programmable protein circuits in living cells
US11965191B2 (en) 2018-01-18 2024-04-23 California Institute Of Technology Programmable protein circuits in living cells
US12286478B2 (en) 2018-01-23 2025-04-29 Nextcure, Inc. B7-H4 antibodies and methods of use thereof
US12145984B2 (en) 2018-01-24 2024-11-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for preventing ischemia reperfusion injury in an organ with antibody antagonists of IL-33
WO2019148089A1 (en) 2018-01-26 2019-08-01 Orionis Biosciences Inc. Xcr1 binding agents and uses thereof
EP3746116A1 (en) 2018-01-31 2020-12-09 Novartis AG Combination therapy using a chimeric antigen receptor
WO2019152895A1 (en) 2018-02-01 2019-08-08 Memorial Sloan Kettering Cancer Center Antibodies to galectin-3 and methods of use thereof
CN112074267B (zh) 2018-02-05 2024-06-28 奥里尼斯生物科学公司股份有限公司 成纤维细胞结合剂及其用途
US12037382B2 (en) 2018-02-05 2024-07-16 Stichting Vu Inverse agonistic anti-US28 antibodies
MX2020008294A (es) 2018-02-06 2020-11-18 Ablynx Nv Metodos de tratamiento de episodio inicial de ttp con dominios variables simples de inmunoglobulina.
WO2019157191A1 (en) 2018-02-07 2019-08-15 Georgia Tech Research Corporation Methods for multiplexed cell isolation using dna gates
WO2019156566A1 (en) 2018-02-12 2019-08-15 Umc Utrecht Holding B.V. Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
WO2019155041A1 (en) 2018-02-12 2019-08-15 Vib Vzw Gβγ COMPLEX ANTIBODIES AND USES THEREOF
WO2019158512A1 (en) 2018-02-13 2019-08-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prognosis and the treatment of glioblastoma
US12246031B2 (en) 2018-02-13 2025-03-11 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
US20210002373A1 (en) 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
WO2019166622A1 (en) 2018-03-01 2019-09-06 Vrije Universiteit Brussel Human pd-l1-binding immunoglobulins
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
CN117964751A (zh) 2018-03-13 2024-05-03 斯米维特公司 与破伤风神经毒素结合的单域抗体
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019178364A2 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
KR102495666B1 (ko) 2018-03-14 2023-02-06 서피스 온콜로지, 인크. Cd39에 결합하는 항체 및 이의 용도
EP3768720A4 (en) 2018-03-20 2022-01-05 Wuxi Biologics Ireland Limited NEW ANTI-BODY ANTI-LAG-3 POLYPEPTIDE
WO2019179420A1 (en) 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel anti-tim-3 antibodies
CN120173101A (zh) 2018-03-22 2025-06-20 表面肿瘤学有限责任公司 抗il-27抗体及其用途
US12281160B2 (en) 2018-03-23 2025-04-22 Csl Limited Method of treating asthma
KR102879500B1 (ko) 2018-03-23 2025-10-31 유니베르시테 리브레 드 브룩크젤즈 Wnt 시그널링 작용제 분자
WO2019184909A1 (zh) 2018-03-27 2019-10-03 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
JP2021519093A (ja) 2018-03-27 2021-08-10 ユーエムシー ユトレヒト ホールディング ビー．ブイ． 微小血管血栓症の処置のための標的化血栓溶解
WO2019185683A1 (en) 2018-03-28 2019-10-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
US11958903B2 (en) 2018-03-30 2024-04-16 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against LAG-3 and uses thereof
WO2019193375A1 (en) 2018-04-04 2019-10-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fzd7 inhibitors for the treatment of retinal neovascularization
AU2019251421B2 (en) 2018-04-09 2025-05-01 Checkmate Pharmaceuticals Packaging oligonucleotides into virus-like particles
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
US20210164984A1 (en) 2018-04-13 2021-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
WO2019207030A1 (en) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
US12048745B2 (en) 2018-05-01 2024-07-30 Augusta University Research Institute, Inc. Methods for detecting and reversing immune therapy resistance
WO2019211369A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
WO2019211370A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
JP7530638B2 (ja) 2018-05-10 2024-08-08 ニューラクル サイエンス カンパニー リミテッド 配列類似性１９、メンバーａ５抗体を有する抗ファミリー及びその使用方法
WO2019217913A1 (en) 2018-05-10 2019-11-14 Sensei Biotherapeutics, Inc. Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
KR20210020903A (ko) 2018-05-14 2021-02-24 하푼 테라퓨틱스, 인크. 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
JP2021525243A (ja) 2018-05-21 2021-09-24 コンパス セラピューティクス リミテッド ライアビリティ カンパニー Ｎｋ細胞による標的細胞の殺傷を増進するための組成物および方法
WO2019226050A2 (en) 2018-05-24 2019-11-28 Wageningen Universiteit Novel viral anti-infective reagents
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
US12404320B2 (en) 2018-05-31 2025-09-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
CN118459594A (zh) 2018-06-01 2024-08-09 诺华股份有限公司 针对bcma的结合分子及其用途
JP7577542B2 (ja) 2018-06-04 2024-11-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
WO2019234099A1 (en) 2018-06-06 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
TWI890660B (zh) 2018-06-13 2025-07-21 瑞士商諾華公司 Bcma 嵌合抗原受體及其用途
EP4365194A3 (en) 2018-06-14 2024-07-24 Regeneron Pharmaceuticals, Inc. Cd79a chimeric antigen receptors
KR20210022004A (ko) 2018-06-18 2021-03-02 안위타 바이오사이언시스, 인코포레이티드 항-메소텔린 작제물 및 이의 용도
MX2020013798A (es) 2018-06-19 2021-08-11 Atarga Llc Moléculas de anticuerpo de componente de complemento 5 y sus usos.
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
JP7538723B2 (ja) 2018-06-28 2024-08-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃ５抗体の産生方法
CN112351998B (zh) 2018-06-29 2022-07-22 苏州智核生物医药科技有限公司 Pd-l1结合多肽及其用途
MX2020013923A (es) 2018-06-29 2021-03-29 Apitbio Inc Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
SG11202100023XA (en) 2018-07-11 2021-01-28 Actym Therapeutics Inc Engineered immunostimulatory bacterial strains and uses thereof
US20210330788A1 (en) 2018-07-11 2021-10-28 Celgene Corporation Uses of anti-bcma chimeric antigen receptors
WO2020016160A1 (en) 2018-07-16 2020-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat neurological diseases
US12485126B2 (en) 2018-07-19 2025-12-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination for treating cancer
BR112021000934A2 (pt) 2018-07-20 2021-04-27 Pierre Fabre Medicament receptor para vista
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
ES2738926A1 (es) 2018-07-26 2020-01-27 Univ Zaragoza Granulisina, metodo de obtencion y usos
US20210186880A1 (en) 2018-08-03 2021-06-24 Brown University Oral formulations with increased uptake
WO2020033923A1 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antigen binding agents that bind cd277 and uses thereof
US12460004B2 (en) 2018-08-09 2025-11-04 Compass Therapeutics Llc Antibodies that bind CD277 and uses thereof
WO2020033925A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
US11453893B2 (en) 2018-08-30 2022-09-27 California Institute Of Technology RNA-based delivery systems with levels of control
WO2020047449A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
SG11202101825QA (en) 2018-08-31 2021-03-30 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP3844180A4 (en) 2018-08-31 2022-07-20 California Institute of Technology Synthetic protein circuits detecting signal transducer activity
KR20210056344A (ko) 2018-09-04 2021-05-18 난징 유엠에이비-바이오파마 컴퍼티 리미티드 융합 단백질 및 그가 종양 및/또는 바이러스 감염을 치료하기 위한 약물 제조에서의 응용
GB201814451D0 (en) 2018-09-05 2018-10-17 Valerie Nicholas Carl Kristoffer Methods
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
WO2020053239A1 (en) 2018-09-11 2020-03-19 Nanotag Biotechnologies Gmbh Epitope tags recognized by specific binders
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856772A1 (en) 2018-09-25 2021-08-04 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
IL281683B2 (en) 2018-09-25 2023-04-01 Harpoon Therapeutics Inc dll3 binding proteins and methods of use
WO2020069372A1 (en) 2018-09-27 2020-04-02 Elstar Therapeutics, Inc. Csf1r/ccr2 multispecific antibodies
CA3113618A1 (en) 2018-09-28 2020-04-02 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
WO2020070062A1 (en) 2018-10-01 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
CN112969503A (zh) 2018-10-03 2021-06-15 斯塔滕生物技术有限公司 对人类和食蟹猕猴apoc3具有特异性的抗体和其使用方法
EP3860653A1 (en) 2018-10-05 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and systems for controlling the agonistic properties of antibody variable domains by light
JP2022504839A (ja) 2018-10-10 2022-01-13 ティロス・セラピューティクス・インコーポレイテッド 抗ｌａｐ抗体変異体及びその使用
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
WO2020080941A1 (en) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
WO2020092549A1 (en) 2018-10-30 2020-05-07 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
US20220000893A1 (en) 2018-10-31 2022-01-06 |Nserm (Institut National De La Santé Et De La Recherche Médicale) Method for treating t-helper type 2 mediated disease
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
GB201818477D0 (en) 2018-11-13 2018-12-26 Emstopa Ltd Tissue plasminogen activator antibodies and method of use thereof
CN119735694A (zh) 2018-11-13 2025-04-01 指南针制药有限责任公司 对抗检查点分子的多特异性结合构建体及其用途
WO2020118293A2 (en) 2018-12-07 2020-06-11 Georgia Tech Research Corporation Antibodies that bind to natively folded myocilin
WO2020120644A1 (en) 2018-12-13 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
SG11202105161YA (en) 2018-12-13 2021-06-29 Surface Oncology Inc Anti-il-27 antibodies and uses thereof
JP2022514280A (ja) 2018-12-20 2022-02-10 ノバルティス アーゲー Ｍｄｍ２阻害剤のための延長低用量レジメン
CA3123338A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
BR112021012027A2 (pt) 2018-12-21 2021-11-03 Ose Immunotherapeutics Molécula bifuncional direcionada contra pd-1 humano
WO2020130838A2 (en) 2018-12-21 2020-06-25 Qvq Holding B.V. Antibodies for preventing or treating candidiasis
CA3122914A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/sirp.alpha. molecule
CN117964756A (zh) 2019-01-02 2024-05-03 纽洛可科学有限公司 抗序列相似家族19成员a5的抗体及其使用方法
CN113574386A (zh) 2019-01-03 2021-10-29 国家医疗保健研究所 用于增强癌症患者的cd8+t细胞依赖性免疫应答的方法和药物组合物
EP3908602A1 (en) 2019-01-07 2021-11-17 Bactolife ApS Pathogen binding proteins
WO2020146627A1 (en) 2019-01-10 2020-07-16 California Institute Of Technology A synthetic system for tunable thresholding of protein signals
AU2020208909B2 (en) 2019-01-15 2025-02-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Mutated interleukin-34 (IL-34) polypeptides and uses thereof in therapy
SG11202107538VA (en) 2019-01-16 2021-08-30 Compass Therapeutics Llc Formulations of antibodies that bind human cd137 and uses thereof
EP3911669A1 (en) 2019-01-16 2021-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Variants of erythroferrone and their use
TWI756621B (zh) 2019-01-25 2022-03-01 大陸商信達生物製藥（蘇州）有限公司 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
KR20210128443A (ko) 2019-02-15 2021-10-26 인테그럴 몰큘러 인코포레이티드 클라우딘 6 항체 및 이의 용도
CA3129317A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
CN119661722A (zh) 2019-02-21 2025-03-21 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
WO2020169707A1 (en) 2019-02-21 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Foxo1 inhibitor for use in the treatment of latent virus infection
CA3130628A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
AU2020226904B2 (en) 2019-02-21 2025-05-01 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
JP7706373B2 (ja) 2019-02-21 2025-07-11 マレンゴ・セラピューティクス，インコーポレーテッド カルレティキュリンに結合する多機能性分子およびその使用
US20220088075A1 (en) 2019-02-22 2022-03-24 The Trustees Of The University Of Pennsylvania Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
MX2021010003A (es) 2019-02-26 2021-12-10 Inspirna Inc Anticuerpos anti-mertk de alta afinidad y usos de los mismos.
US20220144914A1 (en) 2019-03-01 2022-05-12 President And Fellows Of Harvard College Methods and compositions for protein delivery
CN113966397A (zh) 2019-03-08 2022-01-21 黑曜石疗法公司 人碳酸酐酶2组合物和用于可调调节的方法
ES2984072T3 (es) 2019-03-08 2024-10-28 Linxis B V Moléculas de unión internalizantes que actúan sobre receptores implicados en la proliferación celular o en ladiferenciación celular
WO2020193740A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
CN113874392B (zh) 2019-03-28 2025-10-21 丹尼斯科美国公司 工程化抗体
JP2022527790A (ja) 2019-03-29 2022-06-06 アターガ，エルエルシー 抗ｆｇｆ２３抗体分子
WO2020205827A1 (en) 2019-04-01 2020-10-08 Rush University Medical Center Reagents and assays using modified integrin domains
WO2020205409A1 (en) 2019-04-03 2020-10-08 President And Fellows Of Harvard College Ionic liquids for drug delivery
EP3947472A4 (en) 2019-04-04 2023-02-22 Vanderbilt University THERAPEUTIC ANTIBODIES FOR THE TREATMENT OF LUNG CANCER
WO2020208082A1 (en) 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cmv related diseases
US20220168389A1 (en) 2019-04-12 2022-06-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
KR20220016077A (ko) 2019-04-29 2022-02-08 콘포 테라퓨틱스 엔.브이. Gpcr에 결합하는 화합물 및 리간드를 스크리닝하는 키메라 단백질 및 방법
WO2020221888A1 (en) 2019-04-30 2020-11-05 Vib Vzw Cystic fibrosis transmembrane conductance regulator stabilizing agents
SG11202110911RA (en) 2019-05-13 2021-10-28 Regeneron Pharma Improved competitive ligand binding assays
AU2020275002A1 (en) 2019-05-14 2021-12-23 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
EP3969569A1 (en) 2019-05-14 2022-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
EP3969472A1 (en) 2019-05-16 2022-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat type 2 inflammation or mast-cell dependent disease
JP7489407B2 (ja) 2019-05-21 2024-05-23 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
EP3972993A1 (en) 2019-05-21 2022-03-30 Novartis AG Variant cd58 domains and uses thereof
US20220396631A1 (en) 2019-05-21 2022-12-15 Lu HUANG Trispecific binding molecules against bcma and uses thereof
EP3978532A4 (en) 2019-05-24 2023-10-18 Sanyou Biopharmaceuticals Co., Ltd. Novel cldn18.2 binding molecule
EP3976650A1 (en) 2019-05-28 2022-04-06 Vib Vzw Cancer treatment by targeting plexins in the immune compartment
US12472254B2 (en) 2019-05-28 2025-11-18 Vib Vzw CD8+ T-cells lacking plexins and their application in cancer treatment
GB2584441A (en) 2019-06-03 2020-12-09 Fenomark Diagnostics Ab Medical uses, methods and uses
US20220242968A1 (en) 2019-06-04 2022-08-04 Biotheus Inc. Anti-CEACAM5 monoclonal antibody and preparation method thereof and use thereof
CN119613549A (zh) 2019-06-12 2025-03-14 诺华股份有限公司 利钠肽受体1抗体及使用方法
MX2021016098A (es) 2019-06-17 2022-02-03 Visterra Inc Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas.
EP3986453A1 (en) 2019-06-20 2022-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- protease nexin-1 conformational single domain antibodies and uses thereof
EP3986571A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
US20230143091A1 (en) 2019-06-21 2023-05-11 Sorriso Pharmaceuticals, Inc. Compositions
AU2020296979A1 (en) 2019-06-21 2022-02-24 Sorriso Pharmaceuticals, Inc. Polypeptides
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
US20230061378A1 (en) 2019-07-01 2023-03-02 Suzhou Alphamab Co., Ltd. Pertussis toxin binding protein
WO2021001539A1 (en) 2019-07-04 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy to detect and treat eosinophilic fasciitis
AU2020312686A1 (en) 2019-07-15 2022-02-03 Intervet International B.V. Caninized antibodies against canine CTLA-4
KR20220051177A (ko) 2019-07-26 2022-04-26 비스테라, 인크. 인터류킨-2 작용제 및 이의 용도
EP4010079A1 (en) 2019-08-05 2022-06-15 Stichting VU Identification and elimination of hcmv-infected cells
US11680098B2 (en) 2019-08-30 2023-06-20 Agenus Inc. Antibodies that specifically bind human CD96
EP4025608A1 (en) 2019-09-04 2022-07-13 F. Hoffmann-La Roche AG Cd8 binding agents and uses thereof
WO2021044012A1 (en) 2019-09-05 2021-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment and pronostic of acute myeloid leukemia
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
MX2022003005A (es) 2019-09-16 2022-04-07 Surface Oncology Inc Composiciones y metodos de anticuerpos anti-cd39.
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
JP2022549854A (ja) 2019-09-25 2022-11-29 サーフィス オンコロジー インコーポレイテッド 抗ｉｌ－２７抗体及びその使用
TW202126295A (zh) 2019-09-27 2021-07-16 大陸商江蘇挪貝肽醫藥科技有限公司 一種治療心境障礙的方法
EP4034151A1 (en) 2019-09-27 2022-08-03 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of müllerian inhibiting substance inhibitors for treating cancer
TWI878355B (zh) 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
EP3799881A1 (en) 2019-10-04 2021-04-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Single domain antibodies specifically binding globo - series glycans
US20220380456A1 (en) 2019-10-21 2022-12-01 Vib Vzw Nanodisc-specific antigen-binding chimeric proteins
KR20220103947A (ko) 2019-10-21 2022-07-25 노파르티스 아게 베네토클락스 및 tim-3 억제제를 사용한 조합 요법
CN114786680A (zh) 2019-10-21 2022-07-22 诺华股份有限公司 Tim-3抑制剂及其用途
US11459389B2 (en) 2019-10-24 2022-10-04 Massachusetts Institute Of Technology Monoclonal antibodies that bind human CD161
US20230002785A1 (en) 2019-10-28 2023-01-05 Georgia Tech Research Corporation Mrna-encoded antibodies for contraception
WO2021086953A1 (en) 2019-10-28 2021-05-06 Georgia Tech Research Corporation Compositions and methods for prophylaxis of hiv
MX2022005152A (es) 2019-11-05 2022-06-29 Celgene Corp Uso de receptores de antigenos quimericos anti-bcma.
AU2020384953A1 (en) 2019-11-11 2022-06-23 Ibi-Ag Innovative Bio Insecticides Ltd. Insect control nanobodies and uses thereof
JP2023501539A (ja) 2019-11-12 2023-01-18 アクティム・セラピューティクス・インコーポレイテッド 免疫刺激細菌デリバリープラットフォーム、および治療用産物のデリバリーのためのその使用
CN114980864A (zh) 2019-11-22 2022-08-30 哈佛大学校长及研究员协会 用于药物递送的离子液体
AR120566A1 (es) 2019-11-26 2022-02-23 Novartis Ag Receptores de antígeno quiméricos y sus usos
WO2021105391A1 (en) 2019-11-27 2021-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination comprising nupr1 inhibitors to treat cancer
EP4065603A1 (en) 2019-11-27 2022-10-05 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
WO2021105384A1 (en) 2019-11-27 2021-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Targeting the nls region of nupr1 protein to treat cancer
CA3159155A1 (en) 2019-12-05 2021-06-10 Ose Immunotherapeutics Anti-clec-1a antibodies and antigen-binding fragment thereof
WO2021110816A1 (en) 2019-12-06 2021-06-10 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFα AND IL-23
CN114980923A (zh) 2019-12-06 2022-08-30 艾伯霖克斯公司 包含靶向TNFα和OX40L的免疫球蛋白单可变结构域的多肽
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
EP4072682A1 (en) 2019-12-09 2022-10-19 Institut National de la Santé et de la Recherche Médicale (INSERM) Antibodies having specificity to her4 and uses thereof
MY208649A (en) 2019-12-09 2025-05-22 Sanofi Sa Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
TW202136287A (zh) 2019-12-17 2021-10-01 法商Ｏｓｅ免疫治療公司 包含il-7變體之雙官能分子
WO2021119761A1 (en) 2019-12-20 2021-06-24 Hudson Institute of Medical Research Cxcl10 binding proteins and uses thereof
KR20220123013A (ko) 2019-12-20 2022-09-05 모멘타 파머슈티컬스 인코포레이티드 인테그린 알파 11 베타 1에 대한 항체
JP2023506958A (ja) 2019-12-20 2023-02-20 ノバルティス アーゲー 骨髄線維症および骨髄異形成症候群を処置するための、デシタビンまたは抗ｐｄ－１抗体スパルタリズマブを伴うかまたは伴わない抗ｔｉｍ－３抗体ｍｂｇ４５３および抗ｔｇｆ－ベータ抗体ｎｉｓ７９３の組合せ
EP4077372A1 (en) 2019-12-20 2022-10-26 Vib Vzw Nanobody exchange chromatography
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
GB2609554B (en) 2020-01-03 2025-08-20 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
CN114929278A (zh) 2020-01-06 2022-08-19 瓦西尼斯公司 抗ccr8抗体及其用途
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
IL293752A (en) 2020-01-17 2022-08-01 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
US20230076670A1 (en) 2020-01-17 2023-03-09 Universiteit Gent Immunoglobulin single domain antibodies for delivery of mucosal vaccines
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
WO2021163618A1 (en) 2020-02-14 2021-08-19 Novartis Ag Method of predicting response to chimeric antigen receptor therapy
CA3170833A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
JP2023515131A (ja) 2020-02-24 2023-04-12 イマティクス ユーエス，アイエヌシー． がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法
JP2023514654A (ja) 2020-02-25 2023-04-06 ブイアイビー ブイゼットダブリュ ロイシンリッチリピートキナーゼ２のアロステリック調節因子
WO2021173674A1 (en) 2020-02-26 2021-09-02 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
KR20220147109A (ko) 2020-02-27 2022-11-02 노파르티스 아게 키메라 항원 수용체 발현 세포의 제조 방법
AR121461A1 (es) 2020-02-27 2022-06-08 Novartis Ag Métodos para la fabricación de células que expresan el receptor de antígeno quimérico
IL296242A (en) 2020-03-10 2022-11-01 Massachusetts Inst Technology Methods for producing engineered memory-like nk cells and preparations containing them
JP2023517889A (ja) 2020-03-10 2023-04-27 マサチューセッツ インスティテュート オブ テクノロジー ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
JP7765397B2 (ja) 2020-03-12 2025-11-06 イミューン－オーエヌシー セラピューティクス，インコーポレーテッド 新規抗ｌｉｌｒｂ４抗体および派生産物
CN115003333A (zh) 2020-03-13 2022-09-02 江苏恒瑞医药股份有限公司 Pvrig结合蛋白及其医药用途
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
US20230184750A1 (en) 2020-03-20 2023-06-15 Glaxosmithkline Intellectual Property Development Limited Method for detecting polysorbates
WO2021195513A1 (en) 2020-03-27 2021-09-30 Novartis Ag Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
US20230136595A1 (en) 2020-03-30 2023-05-04 Ablynx Nv Method for the production and purification of multivalent immunoglobulin single variable domains
CN113461817B (zh) 2020-03-31 2025-04-18 苏州泽璟生物制药股份有限公司 一种抗人cd47抗体及其抗原结合片段、制备方法和应用
CN121100948A (zh) 2020-03-31 2025-12-12 生物催化公司 抗真菌多肽
CN116710146A (zh) 2020-04-03 2023-09-05 威特拉公司 抗体分子-药物偶联物及其用途
EP4132971A1 (en) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinity matured anti-lap antibodies and uses thereof
IL297200A (en) 2020-04-15 2022-12-01 Voyager Therapeutics Inc tau binding compounds
CN116406287A (zh) 2020-04-16 2023-07-07 巴黎公共医疗救助机构 治疗由病毒引起的补体介导的障碍的方法
WO2021213435A1 (zh) 2020-04-22 2021-10-28 迈威(上海)生物科技股份有限公司 一种靶向人程序性死亡配体1(pd-l1)的单可变域抗体及其衍生物
JP2023523011A (ja) 2020-04-24 2023-06-01 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
EP4143582A4 (en) 2020-05-01 2024-09-25 University of Pittsburgh - of the Commonwealth System of Higher Education COMPOSITIONS AND METHODS FOR IDENTIFYING NANOBODIES AND NANOBODY AFFINITIES
CN116096754A (zh) 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法
JP2023525053A (ja) 2020-05-12 2023-06-14 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 皮膚ｔ細胞リンパ腫及びｔｆｈ由来リンパ腫を処置する新しい方法
WO2021229104A1 (en) 2020-05-15 2021-11-18 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
ES2988406T3 (es) 2020-05-19 2024-11-20 Inst Curie Antagonistas de la ruta de CD44/ácido hialurónico para su uso en un método para el tratamiento del síndrome de liberación de citocinas
KR20230012559A (ko) 2020-05-19 2023-01-26 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 결합 분자
EP3916088A1 (en) 2020-05-28 2021-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins comprising the sars-cov-2 3clpro catalytic domain and their uses for screening anti-sars-cov-2 agents
WO2021242794A2 (en) 2020-05-29 2021-12-02 President And Fellows Of Harvard College Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
AU2021284273A1 (en) 2020-06-02 2022-12-15 Arcus Biosciences, Inc. Antibodies to TIGIT
CN111647077B (zh) 2020-06-02 2021-02-09 深圳市因诺赛生物科技有限公司 新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用
AU2021288224A1 (en) 2020-06-11 2023-01-05 Novartis Ag ZBTB32 inhibitors and uses thereof
CA3187267A1 (en) 2020-06-17 2021-12-23 Janssen Biotech, Inc. Materials and methods for the manufacture of pluripotent stem cells
US20230218608A1 (en) 2020-06-18 2023-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
WO2021262999A1 (en) 2020-06-24 2021-12-30 Visterra, Inc. Antibody molecules to april and uses thereof
CA3187283A1 (en) 2020-06-29 2022-01-06 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-protein s single-domain antibodies and polypeptides comprising thereof
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
US12077576B2 (en) 2020-07-02 2024-09-03 Trustees Of Tufts College VHH polypeptides that bind to Clostridium difficile toxin b and methods of use thereof
CA3188566A1 (en) 2020-07-03 2022-01-06 Suzhou Alphamab Co., Ltd. Coagulation factor xi (fxi) binding protein
CR20230009A (es) 2020-07-16 2023-01-25 Novartis Ag Anticuerpos anti-betacelulina, fragmentos de los mismos, y moléculas de unión multiespecíficas
US20240209089A1 (en) 2020-07-21 2024-06-27 Suzhou Smartnuclide Biopharmaceutical Co., Ltd. Cd8 binding polypeptide and use thereof
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
EP4189061A1 (en) 2020-07-31 2023-06-07 Biotalys NV Methods of increasing recombinant protein yields
CA3190987A1 (en) 2020-08-10 2022-02-17 Janssen Biotech, Inc. Materials and methods for producing bioengineered virus specific lymphocytes
KR20230066000A (ko) 2020-08-12 2023-05-12 액팀 테라퓨틱스, 인코퍼레이티드 면역자극성 박테리아-기초 백신, 치료제, 및 rna 전달 플랫폼
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
KR20230074487A (ko) 2020-08-26 2023-05-30 마렝고 테라퓨틱스, 인크. Trbc1 또는 trbc2를 검출하는 방법
WO2022046920A2 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
AU2021331076A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
KR20230069961A (ko) 2020-09-14 2023-05-19 보르 바이오파마 인크. Cd33에 대한 단일 도메인 항체
WO2022060806A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
EP4214235A1 (en) 2020-09-16 2023-07-26 LinXis B.V. Internalizing binding molecules
EP4216943A1 (en) 2020-09-24 2023-08-02 Vib Vzw Combination of p2y6 inhibitors and immune checkpoint inhibitors
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
KR20230074527A (ko) 2020-09-25 2023-05-30 아블린쓰 엔.브이. Il-13 및 ox40l을 표적으로 하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드
CR20230204A (es) 2020-10-14 2023-10-11 Viridian Therapeutics Inc Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea
EP4232476A2 (en) 2020-10-21 2023-08-30 Boehringer Ingelheim International GmbH Agonistic trkb binding molecules for the treatment of eye diseases
WO2022084399A1 (en) 2020-10-21 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) C-terminal sparc fragments for treating cancer
WO2022098685A2 (en) 2020-11-04 2022-05-12 Celgene Corporation Car t cell therapy in patients who have had prior anti-cancer alkylator therapy
US20240025993A1 (en) 2020-11-06 2024-01-25 Novartis Ag Cd19 binding molecules and uses thereof
AU2021374083A1 (en) 2020-11-06 2023-06-01 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
CN112480248B (zh) 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 与cld18a2特异性结合的分子
US20240018248A1 (en) 2020-12-02 2024-01-18 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
KR20230129018A (ko) 2020-12-04 2023-09-05 비스테라, 인크. 인터류킨-2 작용제를 사용하는 방법
KR20230117383A (ko) 2020-12-04 2023-08-08 셀진 코포레이션 염증-관련 가용성 인자의 억제제와 조합된 키메라 항원수용체 (car) t-세포 요법의 용도
WO2022130182A1 (en) 2020-12-14 2022-06-23 Novartis Ag Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
WO2022129512A1 (en) 2020-12-17 2022-06-23 Ose Immunotherapeutics Bifunctional anti-pd1/il-7 molecules
PH12023500009A1 (en) 2020-12-18 2024-03-11 Ablynx Nv T cell recruiting polypeptides based on tcr alpha/beta reactivity
WO2022129572A1 (en) 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha
EP4262985A1 (en) 2020-12-18 2023-10-25 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
CA3206304A1 (en) 2020-12-24 2022-06-30 Vib Vzw Human ccr8 binders
WO2022136650A1 (en) 2020-12-24 2022-06-30 Oncurious Nv Murine cross-reactive human ccr8 binders
EP4267618A1 (en) 2020-12-24 2023-11-01 Vib Vzw Non-blocking human ccr8 binders
JP2024503506A (ja) 2021-01-20 2024-01-25 ビステラ， インコーポレイテッド インターロイキン－２変異体およびその使用
US20240141060A1 (en) 2021-01-29 2024-05-02 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
GB2603166A (en) 2021-01-29 2022-08-03 Thelper As Therapeutic and Diagnostic Agents and Uses Thereof
WO2022161502A1 (zh) 2021-02-01 2022-08-04 羿尊生物医药（浙江）有限公司 一种靶向蛋白降解系统及其应用
CN117242099A (zh) 2021-02-05 2023-12-15 信立泰生物医药公司 Il-15融合蛋白以及制备和使用其的方法
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
EP4288095A1 (en) 2021-02-05 2023-12-13 Vib Vzw Sarbecovirus binders
EP4291898A1 (en) 2021-02-12 2023-12-20 Institut National de la Santé et de la Recherche Médicale (INSERM) Method for prognosis and treating a patient suffering from cancer
WO2022175392A1 (en) 2021-02-17 2022-08-25 Vib Vzw Inhibition of slc4a4 in the treatment of cancer
MX2023009715A (es) 2021-02-19 2024-01-08 Shaperon Inc Anticuerpo de dominio individual biespecífico contra el ligando de muerte programada (pd-l1) y el cúmulo de diferenciación 47 (cd47) y uso del mismo.
EP4294516A1 (en) 2021-02-19 2023-12-27 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
AU2022222994B2 (en) 2021-02-19 2025-11-27 Shaperon Inc. Single domain antibody against cd47 and use thereof
WO2022177393A1 (ko) 2021-02-19 2022-08-25 (주)샤페론 Pd-l1에 대한 단일 도메인 항체 및 이의 용도
IL305301A (en) 2021-02-19 2023-10-01 Us Health SINGLE DOMAIN ANTIBODIES THAT NEUTRALIZE SARS-CoV-2
CN117321418A (zh) 2021-03-18 2023-12-29 诺华股份有限公司 癌症生物标志物及其使用方法
GB202104104D0 (en) 2021-03-24 2021-05-05 Liliumx Ltd Platform and method
WO2022199804A1 (en) 2021-03-24 2022-09-29 Vib Vzw Nek6 inhibition to treat als and ftd
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
AU2022253223A1 (en) 2021-04-07 2023-09-28 Century Therapeutics, Inc. Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
CA3214473A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
MX2023011927A (es) 2021-04-07 2023-10-23 Century Therapeutics Inc Composiciones y metodos para la generacion de linfocitos t gamma-delta a partir de celulas madre pluripotentes inducidas.
KR20240004462A (ko) 2021-04-08 2024-01-11 마렝고 테라퓨틱스, 인크. Tcr에 결합하는 다기능성 분자 및 이의 용도
EP4320229A1 (en) 2021-04-09 2024-02-14 Stichting Radboud Universiteit Off the shelf proximity biotinylation enzyme
IL307419A (en) 2021-04-09 2023-12-01 Ose Immunotherapeutics A new scaffold for bifunctional molecules with improved properties
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
WO2022219080A1 (en) 2021-04-14 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve nk cells cytotoxicity
EP4322937A1 (en) 2021-04-14 2024-02-21 Institut National de la Santé et de la Recherche Médicale (INSERM) New method to improve the anti-tumoral activity of macrophages
IL307598A (en) 2021-04-16 2023-12-01 Juno Therapeutics Inc T-cell therapy in patients who have had a previous stem cell transplant
MX2023012974A (es) 2021-05-04 2023-11-15 Regeneron Pharma Agonistas multiespecificos de receptores del fgf21 y sus usos.
CA3215856A1 (en) 2021-05-07 2022-11-10 Alison O'neill Anti-il-27 antibodies and uses thereof
US20240261446A1 (en) 2021-05-17 2024-08-08 Université de Liège Anti-cd38 single domain antibodies in disease monitoring and treatment
EP4340879A4 (en) 2021-05-20 2025-03-26 Dianthus Therapeutics OpCo, Inc. Antibodies that bind to c1s and uses thereof
WO2022253910A1 (en) 2021-06-02 2022-12-08 INSERM (Institut National de la Santé et de la Recherche Médicale) A new method to treat an inflammatory skin disease
US20250019446A1 (en) 2021-06-16 2025-01-16 Shanghai Sinobay Biotechnology Co., Ltd. Antibody Targeting Axl Protein and Antigen Binding Fragment Thereof, and Preparation Method Therefor and Application Thereof
CN117957256A (zh) 2021-06-17 2024-04-30 勃林格殷格翰国际有限公司 新颖三特异性结合分子
EP4359437A2 (en) 2021-06-22 2024-05-01 Merck Patent GmbH Vhh-based nkp30 binders
EP4359421A1 (en) 2021-06-23 2024-05-01 Vib Vzw Means and methods for selection of specific binders
US20230174651A1 (en) 2021-06-23 2023-06-08 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
CN114230665B (zh) 2021-06-23 2024-03-22 苏州智核生物医药科技有限公司 CD8α结合多肽及其用途
US20240343811A1 (en) 2021-06-29 2024-10-17 Shandong Simcere Biopharmacutical Co., Ltd. Cd16 antibody and use thereof
US20240382628A1 (en) 2021-07-15 2024-11-21 President And Fellows Of Harvard College Compositions and methods relating to cells with adhered particles
WO2023006040A1 (zh) 2021-07-30 2023-02-02 江苏先声药业有限公司 抗pvrig/抗tigit双特异性抗体和应用
CA3228014A1 (en) 2021-07-30 2023-02-16 Vib Vzm Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
US20240336679A1 (en) 2021-08-06 2024-10-10 Institut Regional Du Cancer De Montpellier Methods for the treatment of cancer
TW202320850A (zh) 2021-08-10 2023-06-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物、劑量及方法
WO2023023220A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
WO2023023227A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
CN117616049A (zh) 2021-08-24 2024-02-27 江苏恒瑞医药股份有限公司 Fap/cd40结合分子及其医药用途
CA3231553A1 (en) 2021-09-15 2023-03-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody
WO2023041985A2 (en) 2021-09-15 2023-03-23 New York University In Abu Dhabicorporation Compositions that block activation of the sars-cov-2 replication and transcription complex (rtc) and methods of use thereof
TW202328195A (zh) 2021-09-15 2023-07-16 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｐｄ－１的蛋白及其醫藥用途
WO2023041744A1 (en) 2021-09-17 2023-03-23 Institut Curie Bet inhibitors for treating pab1 deficient cancer
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023057484A1 (en) 2021-10-06 2023-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
WO2023057601A1 (en) 2021-10-06 2023-04-13 Biotalys NV Anti-fungal polypeptides
CN118382429A (zh) 2021-10-08 2024-07-23 哈佛大学校长及研究员协会 用于药物递送的离子液体
JP2024539749A (ja) 2021-10-14 2024-10-29 ラッティコン （スージョウ） バイオファーマシューティカルズ カンパニー リミテッド 新規な抗体－サイトカイン融合タンパク質及びその製造方法と使用
WO2023073099A1 (en) 2021-10-28 2023-05-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis
WO2023078906A1 (en) 2021-11-03 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating acute myeloid leukemia
EP4177266A1 (en) 2021-11-05 2023-05-10 Katholieke Universiteit Leuven Neutralizing anti-sars-cov-2 human antibodies
WO2023079137A1 (en) 2021-11-05 2023-05-11 Katholieke Universiteit Leuven Neutralizing anti-sars-cov-2 human antibodies
US20250026839A1 (en) 2021-11-09 2025-01-23 Ose Immunotherapeutics Identification of CLEC-1 Ligand and Uses Thereof
EP4429682A2 (en) 2021-11-09 2024-09-18 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
EP4180518A1 (en) 2021-11-12 2023-05-17 Istituto Europeo di Oncologia S.r.l. T cells and uses thereof
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
US20250019708A1 (en) 2021-11-19 2025-01-16 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
WO2023089159A1 (en) 2021-11-22 2023-05-25 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy targeting stroma/tumor cell crosstalk to treat a cancer
EP4437547A1 (en) 2021-11-22 2024-10-02 Ablynx N.V. Obtaining sequence information for target multivalent immunoglobulin single variable domains
WO2023095034A1 (en) 2021-11-24 2023-06-01 Novartis Ag Modulators of adeno-associated virus transduction and uses thereof
US20230348614A1 (en) 2021-11-24 2023-11-02 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
EP4435002A4 (en) 2021-11-29 2025-03-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. MODIFIED PROTEIN OR POLYPEPTIDE
EP4442273A4 (en) 2021-11-30 2025-12-24 Suzhou Alphamab Co Ltd METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOEMBOLIC DISEASES
JP2024543209A (ja) 2021-12-01 2024-11-19 ビステラ， インコーポレイテッド インターロイキン－２剤の使用方法
EP4428156A4 (en) 2021-12-03 2025-05-28 Shandong Simcere Biopharmaceutical Co., Ltd. ANTI-BCMA NANOBODY AND USE THEREOF
WO2023099763A1 (en) 2021-12-03 2023-06-08 Institut Curie Sirt6 inhibitors for use in treating resistant hrd cancer
IL313473A (en) 2021-12-15 2024-08-01 Interius Biotherapeutics Inc Pseudotyped viral particles, compositions comprising the same, and uses thereof
JP2024546916A (ja) 2021-12-17 2024-12-26 アブリンクス エン．ヴェー． ＴＣＲαβ、ＣＤ３３及びＣＤ１２３を標的とする免疫グロブリン単一可変ドメインを含むポリペプチド
US20250145705A1 (en) 2021-12-31 2025-05-08 Shandong Simcere Biopharmaceutical Co., Ltd. Gprc5d antibody and application thereof
EP4209508A1 (en) 2022-01-11 2023-07-12 Centre national de la recherche scientifique Nanobodies for the deneddylating enzyme nedp1
US20250304664A1 (en) 2022-01-12 2025-10-02 Vib Vzw Human NTCP Binders For Therapeutic Use And Liver-Specific Targeted Delivery
GB202201137D0 (en) 2022-01-28 2022-03-16 Thelper As Therapeutic and diagnostic agents and uses thereof
AU2023212994A1 (en) 2022-01-28 2024-08-08 Georgiamune Inc. Antibodies to programmed cell death protein 1 that are pd-1 agonists
WO2023148291A1 (en) 2022-02-02 2023-08-10 Biotalys NV Methods for genome editing
US20230383010A1 (en) 2022-02-07 2023-11-30 Visterra, Inc. Anti-idiotype antibody molecules and uses thereof
WO2023148397A1 (en) 2022-02-07 2023-08-10 Vib Vzw Engineered stabilizing aglycosylated fc-regions
EP4476355A1 (en) 2022-02-11 2024-12-18 Henkel AG & Co. KGaA Process for the synthesis of alpha-methylene-gamma-butyrolactone
US20250144042A1 (en) 2022-02-22 2025-05-08 Brown University Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
US20250195633A1 (en) 2022-03-23 2025-06-19 Bodhi Bio Llc Antigen-specific therapy for autoimmune diseases
TW202405009A (zh) 2022-03-30 2024-02-01 瑞士商諾華公司 使用抗利尿鈉肽受體１（ｎｐｒ１）抗體治療障礙之方法
EP4507794A1 (en) 2022-04-11 2025-02-19 Vor Biopharma Inc. Binding agents and methods of use thereof
EP4508074A1 (en) 2022-04-13 2025-02-19 Ose Immunotherapeutics New class of molecules for selective clearance of antibody
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023198851A1 (en) 2022-04-14 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
TW202400637A (zh) 2022-04-25 2024-01-01 美商威特拉公司 April之抗體分子及其用途
WO2023212587A1 (en) 2022-04-28 2023-11-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant polypeptides comprising single-domain antibodies targeting herv-k subtype hml-2
JP2025516262A (ja) 2022-05-02 2025-05-27 アーカス バイオサイエンシズ インコーポレイティド 抗ｔｉｇｉｔ抗体及びその使用
WO2023213751A1 (en) 2022-05-02 2023-11-09 Umc Utrecht Holding B.V Single domain antibodies for the detection of plasmin-cleaved vwf
CN119032105A (zh) 2022-05-07 2024-11-26 北京拓界生物医药科技有限公司 松弛素或类似物的融合蛋白及其医药用途
EP4522630A1 (en) 2022-05-10 2025-03-19 Institut National de la Santé et de la Recherche Médicale Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
US20250340668A1 (en) 2022-05-11 2025-11-06 Regeneron Pharmaceuticals, Inc. Multispecific binding molecule proproteins and uses thereof
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
US20250295809A1 (en) 2022-05-13 2025-09-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
TWI866210B (zh) 2022-05-17 2024-12-11 大陸商蘇州創勝醫藥集團有限公司 雙功能蛋白質及其製劑和用途
IL316708A (en) 2022-05-18 2024-12-01 Vib Vzw Cerbevirus S2 spike subunit binding
US20230372395A1 (en) 2022-05-19 2023-11-23 Massachusetts Institute Of Technology Car cells targeting an inserted ligand
EP4527853A1 (en) 2022-05-19 2025-03-26 Shaperon Inc. Bispecific humanized single domain antibody to pd-l1 and cd47, and use thereof
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230116A1 (en) 2022-05-25 2023-11-30 Surface Oncology, Inc. Use of anti-il-27 antibodies
US20240026001A1 (en) 2022-05-25 2024-01-25 Surface Oncology, Inc. Use of anti-il-27 antibodies
US20250297324A1 (en) 2022-05-30 2025-09-25 Ose Immunotherapeutics Biomarkers of IL7R Modulator Activity
WO2023232036A1 (zh) 2022-05-31 2023-12-07 明济生物制药（北京）有限公司 抗cd40抗体和抗pd-l1×cd40双特异抗体及其应用
WO2023236889A1 (zh) 2022-06-06 2023-12-14 山东先声生物制药有限公司 靶向bcma、gprc5d和t细胞的多特异性抗体及其应用
JP2025519477A (ja) 2022-06-07 2025-06-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｔ細胞活性を調節するための多重特異性分子及びその使用
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
AU2023285094A1 (en) 2022-06-08 2025-01-23 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
AU2023290487A1 (en) 2022-06-14 2025-01-30 Ablynx Nv Immunoglobulin single variable domains targeting t cell receptor
WO2024003873A1 (en) 2022-06-30 2024-01-04 Intrexon Actobiotics Nv D/B/A Precigen Actobio Single variable domain antibodies against tumor necrosis factor-alpha
EP4299124A1 (en) 2022-06-30 2024-01-03 Universite De Montpellier Anti-mglur2 nanobodies for use as biomolecule transporter
EP4299125A1 (en) 2022-06-30 2024-01-03 Universite De Montpellier Anti-mglur2 biparatopic nanobodies and uses thereof
JP2025523630A (ja) 2022-07-04 2025-07-23 ブイアイビー ブイゼットダブリュ 血液－脳脊髄液関門通過抗体
WO2024008904A2 (en) 2022-07-08 2024-01-11 Novo Nordisk A/S Highly potent isvd compounds capable of substituting for fviii(a)
US12098400B2 (en) 2022-07-08 2024-09-24 Novo Nordisk A/S Highly potent ISVD compounds capable of substituting for FVIII(A)
CA3259402A1 (en) 2022-07-15 2024-01-18 Boehringer Ingelheim International Gmbh BINDING MOLECULES FOR CANCER TREATMENT
AU2023310814A1 (en) 2022-07-18 2025-03-06 Ablynx N.V. Cx3cr1-binding compounds, uses thereof and related methods
JP2025525612A (ja) 2022-07-22 2025-08-05 ヤンセン バイオテツク，インコーポレーテツド エフェクター免疫細胞への遺伝的命令の増強された移入
TW202409288A (zh) 2022-07-25 2024-03-01 美商英特瑞斯生物療法公司 突變多肽、包含該等突變多肽之組合物及其用途
TW202423965A (zh) 2022-07-27 2024-06-16 比利時商艾伯霖克斯公司 與新生兒fc受體的特定表位結合之多肽
EP4565607A1 (en) 2022-08-01 2025-06-11 Ose Immunotherapeutics Heterodimeric fc-clec-1 fusion molecule and uses thereof
JP2025525886A (ja) 2022-08-02 2025-08-07 オーエスイー・イミュノセラピューティクス Ｃｄ２８に対する多機能性分子
JP2025528068A (ja) 2022-08-03 2025-08-26 ボイジャー セラピューティクス インコーポレイテッド 血液脳関門を通過させるための組成物及び方法
WO2024028476A1 (en) 2022-08-05 2024-02-08 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of th2-mediated diseases
WO2024037910A1 (en) 2022-08-17 2024-02-22 Institut National de la Santé et de la Recherche Médicale Syk inhibitors for use in the treatment of cancer
CA3265385A1 (en) 2022-08-22 2024-02-29 Abdera Therapeutics Inc. DLL3 BINDING MOLECULES AND THEIR USES
WO2024047110A1 (en) 2022-08-31 2024-03-07 Institut National de la Santé et de la Recherche Médicale Method to generate more efficient car-t cells
JP2025531719A (ja) 2022-08-31 2025-09-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 鎌状赤血球症の治療のための融合ポリペプチドの投薬及び投与
JP2025529210A (ja) 2022-09-01 2025-09-04 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法
CA3266977A1 (en) 2022-09-06 2024-03-14 Alexion Pharmaceuticals, Inc. DIAGNOSTIC AND PROGNOSIS BIOMARKER PROFILES IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA)
CA3266599A1 (en) 2022-09-07 2024-11-07 Quantitative Biosciences, Inc. UNIQUE VARIABLE DOMAIN ANTIBODIES SPECIFIC TO FENTANYL AND USE IN A CONTINUOUS AGGLUTINATION TEST
CN120112550A (zh) 2022-09-09 2025-06-06 耶鲁大学 蛋白水解靶向抗体及其使用方法
CN120019071A (zh) 2022-09-15 2025-05-16 沃雅戈治疗公司 Tau结合化合物
KR20250067174A (ko) 2022-09-15 2025-05-14 노파르티스 아게 키메라 항원 수용체 요법을 사용한 자가면역 장애의 치료
WO2024068744A1 (en) 2022-09-27 2024-04-04 Vib Vzw Antivirals against human parainfluenza virus
KR20250131767A (ko) 2022-09-28 2025-09-03 발린크 테라퓨틱스 리미티드 다가 단백질 및 스크리닝 방법
TW202430561A (zh) 2022-09-30 2024-08-01 法商賽諾菲公司 抗cd28抗體
WO2024074713A1 (en) 2022-10-07 2024-04-11 Institut National de la Santé et de la Recherche Médicale Method to generate improving car-t cells
EP4605077A1 (en) 2022-10-18 2025-08-27 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2024088424A1 (zh) 2022-10-28 2024-05-02 嘉和生物药业有限公司 新型抗ctla4抗体
WO2024096735A1 (en) 2022-10-31 2024-05-10 Stichting Amsterdam UMC Single domain anti-cd169 antibodies
JP2025537215A (ja) 2022-11-02 2025-11-14 ▲蘇▼州康▲寧▼杰瑞生物科技有限公司 Ｇｉｐｒ結合タンパク質及びその使用
WO2024101989A1 (en) 2022-11-08 2024-05-16 Stichting Amsterdam UMC Activation inducible antigen receptors for adoptive immunotherapy
KR20250134582A (ko) 2022-11-10 2025-09-11 이뮤비아 인코포레이티드 Dr5 및 muc16에 결합하는 세포독성 이중특이성 항체 및 이의 용도
JP2025537809A (ja) 2022-11-15 2025-11-20 アイメック・ヴェーゼットウェー 液滴操作のための方法およびシステム
IL320903A (en) 2022-11-21 2025-07-01 Dianthus Therapeutics Opco Inc Antibodies that bind to C1S and their uses
CN120077072A (zh) 2022-11-29 2025-05-30 江苏恒瑞医药股份有限公司 Cldn18.2/4-1bb结合蛋白及其医药用途
CN120282987A (zh) 2022-11-30 2025-07-08 因特格尔莫来库乐有限公司 包括双特异性型式的针对紧密连接蛋白6的抗体
KR20250114116A (ko) 2022-12-01 2025-07-28 제너레이션 바이오 컴퍼니 세포 표적화를 위한 스텔스 지질 나노입자 조성물
WO2024123963A2 (en) 2022-12-07 2024-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing monoclonal antibodies against western, eastern, and venezuelan equine encephalitis virus (eev)
WO2024126363A1 (en) 2022-12-12 2024-06-20 Institut National de la Santé et de la Recherche Médicale Image-based high-content screening methods for identifying compounds targeting apicomplexan parasites
WO2024126805A1 (en) 2022-12-15 2024-06-20 Aarhus Universitet Synthetic activation of multimeric transmembrane receptors
WO2024133301A1 (en) 2022-12-19 2024-06-27 Umc Utrecht Holding B.V. Btn2a1 binding peptide
US12195546B2 (en) 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies
EP4638502A2 (en) 2022-12-21 2025-10-29 Genzyme Corporation Anti-pd-1×4-1bb binding proteins
WO2024133723A1 (en) 2022-12-22 2024-06-27 Institut National de la Santé et de la Recherche Médicale Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
WO2024133937A1 (en) 2022-12-22 2024-06-27 Biotalys NV Methods for genome editing
TW202440614A (zh) 2022-12-23 2024-10-16 比利時商艾伯霖克斯公司 基於蛋白質的接合載體
CN120476149A (zh) 2022-12-23 2025-08-12 成都恩沐生物科技有限公司 靶向gprc5d的多特异性多肽复合物
EP4642235A1 (en) 2022-12-29 2025-11-05 Biotalys NV Agrochemical compositions
CN120475992A (zh) 2022-12-29 2025-08-12 苏州创胜医药集团有限公司 含有治疗性抗体的药物制剂及其用途
WO2024141645A1 (en) 2022-12-30 2024-07-04 Biotalys N.V. Agglomerate
WO2024143925A1 (ko) 2022-12-30 2024-07-04 연세대학교 산학협력단 Rnase a에 특이적으로 결합하는 항체 또는 펩티드, 및 rnase a 검출 면역분석 장치 및 방법 그리고 rnase a 포집 방법
EP4642232A1 (en) 2022-12-30 2025-11-05 Biotalys NV Self-emulsifiable concentrate
EP4642916A2 (en) 2022-12-30 2025-11-05 Biotalys NV Secretion signals
CN120529914A (zh) 2023-01-09 2025-08-22 奥德赛治疗股份有限公司 抗tnfr2抗原结合蛋白及其用途
CN120418286A (zh) 2023-01-09 2025-08-01 北京拓界生物医药科技有限公司 TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途
US20240247069A1 (en) 2023-01-13 2024-07-25 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
TW202434629A (zh) 2023-01-26 2024-09-01 愛爾蘭商歐薩爾普羅席納有限公司 以抗類澱粉β (ABETA)抗體治療神經病症之方法
WO2024156881A1 (en) 2023-01-27 2024-08-02 Vib Vzw CD8b-BINDING POLYPEPTIDES
WO2024156888A1 (en) 2023-01-27 2024-08-02 Vib Vzw Cd163-binding conjugates
IL322269A (en) 2023-02-06 2025-09-01 Merck Patent Gmbh VHH-based NKP46 binding agents
WO2024168061A2 (en) 2023-02-07 2024-08-15 Ayan Therapeutics Inc. Antibody molecules binding to sars-cov-2
EP4662246A1 (en) 2023-02-09 2025-12-17 Seni-Preps B.V. Immunoglobulin single variable domains that inhibit urease and use thereof
IL322564A (en) 2023-02-10 2025-10-01 Amunix Pharmaceuticals Inc Prostate-specific membrane antigen (PSMA)-targeting compositions and methods for their preparation and use
CN120712282A (zh) 2023-02-17 2025-09-26 阿布林克斯有限公司 结合新生儿fc受体的多肽
KR20250153801A (ko) 2023-02-21 2025-10-27 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Il-36r 결합 단백질 및 이의 의학적 용도
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors
WO2024175105A1 (zh) 2023-02-24 2024-08-29 上海迈晋生物医药科技有限公司 一种fap/cd40结合分子的药物组合物及其医药用途
WO2024184812A1 (en) 2023-03-06 2024-09-12 Beigene Switzerland Gmbh Anti-cldn6 antibodies and methods of use
AR132062A1 (es) 2023-03-06 2025-05-21 Beigene Switzerland Gmbh Anticuerpos multiespecíficos anti-cd3 y métodos de uso
WO2024184810A1 (en) 2023-03-06 2024-09-12 Beigene Switzerland Gmbh Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
CN120858176A (zh) 2023-03-07 2025-10-28 居里研究所 Brca相关癌症中的ung/udg抑制
WO2024184479A1 (en) 2023-03-08 2024-09-12 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of food allergy
US20240344078A1 (en) 2023-03-14 2024-10-17 Aarhus Universitet Genetically altered nfr5 receptor kinases
TW202444757A (zh) 2023-03-14 2024-11-16 美商奧迪希治療公司 抗cd25抗原結合蛋白及其用途
WO2024194673A1 (en) 2023-03-21 2024-09-26 Institut Curie Methods for the treatment of dedifferentiated liposarcoma
WO2024194401A1 (en) 2023-03-21 2024-09-26 Institut Curie Vps4b inhibitor for use in methods for the treatment of hrd cancer
WO2024194402A1 (en) 2023-03-21 2024-09-26 Institut Curie Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
WO2024197296A1 (en) 2023-03-23 2024-09-26 Bodhi Bio Llc Compositions and methods for antigen-specific therapy
EP4435005A1 (en) 2023-03-24 2024-09-25 Sanofi Asthma treatment by blocking il-13 and tslp
AU2024247861A1 (en) 2023-03-24 2025-11-06 Sanofi Asthma treatment by blocking il-13 and tslp
WO2024200846A1 (en) 2023-03-30 2024-10-03 272BIO Limited Gnrh-binding polypeptides and uses thereof
WO2024208816A1 (en) 2023-04-03 2024-10-10 Vib Vzw Blood-brain barrier crossing antibodies
WO2024213782A1 (en) 2023-04-13 2024-10-17 Institut Curie Methods for the treatment of t-cell acute lymphoblastic leukemia
WO2024224323A1 (en) 2023-04-24 2024-10-31 King Abdullah University Of Science Of Technology Compositions, systems and methods for multiplex detection of target biomarkers in a sample
WO2024226829A2 (en) 2023-04-26 2024-10-31 Yale University Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer
WO2024231447A1 (en) 2023-05-08 2024-11-14 Sanofi Glycosylation of immunoglobulin single variable domains
WO2024231348A1 (en) 2023-05-11 2024-11-14 Vib Vzw Slc4a4/nbce1 inhibitors
WO2024238565A1 (en) 2023-05-15 2024-11-21 Vor Biopharma Inc. Egf-like module containing mucin-like hormone-like 2 (erm2) binding agents and methods of use thereof
AU2024273077A1 (en) 2023-05-17 2025-11-13 Odyssey Therapeutics, Inc. Modified single-domain antibodies
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2024240162A1 (en) 2023-05-23 2024-11-28 Shanghai Allygen Biologics Co., Ltd. Pd-l1 and trop-2 targeting conjugates comprising effector molecules and uses thereof
WO2024251826A1 (en) 2023-06-05 2024-12-12 Vib Vzw Glyco-engineered antibody-drug-conjugates comprising an oxime linker
WO2024251783A1 (en) 2023-06-05 2024-12-12 Sanofi Predicting thermal stabilities of immunoglobulin single variable domains using machine-learning models
WO2024251983A1 (en) 2023-06-09 2024-12-12 Merck Patent Gmbh Il-18 mimetics
WO2024251981A1 (en) 2023-06-09 2024-12-12 Umc Utrecht Holding B.V. Detecting and/or modulating susceptibility to btn2a1 and/or btn3a1 targeting therapeutics
WO2024256527A1 (en) 2023-06-13 2024-12-19 Institut National de la Santé et de la Recherche Médicale Use of a cxcl 10 inhibitor for the treatment of transplant vasculopathy
WO2024259305A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Vhh polypeptides that bind to mesothelin, compositions and methods of use thereof
AR133055A1 (es) 2023-06-22 2025-08-20 Ablynx Nv Dominios variables únicos de inmunoglobulina dirigidos a pd-l1
WO2024261235A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Chimeric proteins for modulating cytokine receptor activity
WO2024261344A1 (en) 2023-06-23 2024-12-26 Vib Vzw Novel binders targeting the multi-drug resistant pathogen acinetobacter baumannii
AR133108A1 (es) 2023-06-29 2025-08-27 Odyssey Therapeutics Inc Proteínas de unión a antígeno anti-trailr2 y sus usos
EP4483951A1 (en) 2023-06-30 2025-01-01 Université de Liège Single-domain antibody for inhibition of neutrophil elastase activity
WO2025007195A1 (en) 2023-07-05 2025-01-09 CSL Innovation Pty Ltd Methods of treating or preventing a complication of sickle cell disease
TW202517676A (zh) 2023-07-05 2025-05-01 比利時商艾伯霖克斯公司 用於治療ＩｇＧ相關疾病及病症之改良ＦｃＲｎ拮抗劑
WO2025014773A1 (en) 2023-07-07 2025-01-16 Viridian Therapeutics, Inc. Methods of treating chronic thyroid eye disease
WO2025024645A1 (en) 2023-07-25 2025-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rapid method for producing antibodies
WO2025032112A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of type 2-mediated diseases
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025032158A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Method to treat tauopathies
WO2025032213A1 (en) 2023-08-10 2025-02-13 Ose Immunotherapeutics Identification of hla-dra as a ligand of clec-1 and uses thereof
WO2025036848A1 (en) 2023-08-11 2025-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Anti-muc16 antibodies and uses thereof
EP4512243A1 (en) 2023-08-21 2025-02-26 Kymab Limited Binding molecules
TW202525843A (zh) 2023-09-04 2025-07-01 法商賽諾菲公司 用於治療表現磷脂醯肌醇蛋白聚糖-3之腫瘤的多肽
WO2025059487A2 (en) 2023-09-15 2025-03-20 Othair Prothena Limited Cell penetrating agents and uses thereof
GB202314424D0 (en) 2023-09-20 2023-11-01 Cambridge Entpr Ltd A conjugate
WO2025061919A1 (en) 2023-09-22 2025-03-27 Ablynx Nv Bi- and multivalent albumin binders
WO2025068393A1 (en) 2023-09-27 2025-04-03 Institut Curie Methods for the treatment of fibrotic related diseases
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025073890A1 (en) 2023-10-06 2025-04-10 Institut National de la Santé et de la Recherche Médicale Method to capture circulating tumor extracellular vesicles
WO2025078418A1 (en) 2023-10-10 2025-04-17 Nano Tag Biotechnologies Gmbh Humanized single-domain antibodies binding to epitope tags
TW202535921A (zh) 2023-10-11 2025-09-16 德商拜恩迪克公司 用於靶向遞送免疫效應子細胞之試劑及方法
WO2025078851A1 (en) 2023-10-11 2025-04-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods of treating cognitive deficit
TW202515903A (zh) 2023-10-12 2025-04-16 瑞士商百濟神州瑞士有限責任公司 手術前後基於抗ｐｄ－１之治療
NL2036011B1 (en) 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants
TW202530265A (zh) 2023-10-13 2025-08-01 美商奧迪希治療公司 抗cdh17抗原結合蛋白及其用途
WO2025093541A1 (en) 2023-10-31 2025-05-08 Ose Immunotherapeutics Combination of interleukin 7 and tumour associated antigen vaccine
WO2025093683A1 (en) 2023-11-03 2025-05-08 Neuvasq Biotechnologies Sa Wnt7 signaling agonists
WO2025099632A1 (en) 2023-11-08 2025-05-15 Sanofi Cd25 based lysosomal degrader and uses thereof
WO2025109176A1 (en) 2023-11-22 2025-05-30 Exevir Bio Bv Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
US20250296991A1 (en) 2023-12-01 2025-09-25 Ablynx N.V. Precision activated polypeptides
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025125577A1 (en) 2023-12-14 2025-06-19 Vib Vzw Antibodies against influenza b virus
WO2025136985A1 (en) 2023-12-17 2025-06-26 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
WO2025132833A1 (en) 2023-12-20 2025-06-26 Institut National de la Santé et de la Recherche Médicale Anti trypsin-3 single domain antibody
WO2025133166A1 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based carriers for site-specific amine conjugation
WO2025133252A1 (en) 2023-12-22 2025-06-26 Ablynx Nv Immunoglobulin single variable domains targeting ceacam5
WO2025133253A2 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery
EP4574981A1 (en) 2023-12-22 2025-06-25 Biotalys NV Anti-fungal vhh antibodies
WO2025151492A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151502A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Modified antibodies
WO2025151496A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025154056A1 (en) 2024-01-21 2025-07-24 Ibi-Ag Innovative Bio Insecticides Ltd. Anti-insect cda nanobodies and uses thereof
WO2025154058A1 (en) 2024-01-21 2025-07-24 Ibi-Ag Innovative Bio Insecticides Ltd. Anti-insect hsp70 nanobodies and uses thereof
WO2025160546A1 (en) 2024-01-26 2025-07-31 The Johns Hopkins University Dendrimer conjugate compositions for intracellular delivery of antibodies and antibody fragments
WO2025162980A1 (en) 2024-01-30 2025-08-07 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of breast cancer using a jnk-1 inhibitor
WO2025168716A1 (en) 2024-02-07 2025-08-14 Eyebiotech Limited Compositions, doses, and methods for treatment of ocular diseases
WO2025174825A2 (en) 2024-02-12 2025-08-21 Aera Therapeutics, Inc. Delivery compositions
WO2025176777A1 (en) 2024-02-20 2025-08-28 Institut Curie Dut inhibition in homologous recombination deficiency cancer
WO2025178959A1 (en) 2024-02-20 2025-08-28 University Of Georgia Research Foundation, Inc. Single-domain antibodies and variants thereof against tab1
WO2025181155A1 (en) 2024-02-26 2025-09-04 Vib Vzw Human beta-glucocerebrosidase binders and uses thereof
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2025184211A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates
WO2025191018A1 (en) 2024-03-13 2025-09-18 Institut National de la Santé et de la Recherche Médicale Mrgpre binding agent for use in the treatment of inflammatory and pain disorders
WO2025196308A1 (en) 2024-03-22 2025-09-25 Vib Vzw Means and methods for displaying fc-containing proteins on cells and selection thereof
WO2025207946A1 (en) 2024-03-28 2025-10-02 Genzyme Corporation Polypeptides binding to a specific epitope of the transferrin receptor 1
WO2025212726A2 (en) 2024-04-04 2025-10-09 Compass Therapeutics, Inc. Combination of antibodies targeting dll4/vegf and cd137 agonists or anti-pd1/anti-pd-l1 antibodies for the treatment of cancer
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2025219231A1 (en) 2024-04-15 2025-10-23 Vib Vzw Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
WO2025226603A1 (en) 2024-04-22 2025-10-30 Surface Oncology, LLC Methods for treating cancer using anti-ccr8 antibodies
WO2025224050A1 (en) 2024-04-22 2025-10-30 Institut National de la Santé et de la Recherche Médicale Methods of treatment of patients suffering from hypomelanosis of ito
WO2025224297A1 (en) 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof
WO2025231143A1 (en) 2024-04-30 2025-11-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies against ev-d68
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025238157A1 (en) 2024-05-15 2025-11-20 Katholieke Universiteit Leuven Multispecific binding agent suitable for use in cancer immune therapy
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2025242836A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
WO2025245381A1 (en) 2024-05-23 2025-11-27 The Trustrees Of Dartmouth College Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues
WO2025255558A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
WO2025255435A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Antigen-binding proteins against serum albumin and uses thereof
WO2025257408A1 (en) 2024-06-14 2025-12-18 Sanofi Treatment of solid organ transplant subjects with cd28/ox40 bispecific antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9016299D0 (en) * 1990-07-25 1990-09-12 Brien Caroline J O Binding substances

Also Published As

Publication number Publication date
PT656946E (pt) 2001-12-28
DE69334275D1 (de) 2009-05-20
EP2192131A1 (en) 2010-06-02
DK0656946T3 (da) 2001-11-05
DE69334305D1 (de) 2010-01-28
DE69330523D1 (de) 2001-09-06
JP2009280608A (ja) 2009-12-03
DK0656946T4 (da) 2010-07-26
JPH08500487A (ja) 1996-01-23
JP3444885B2 (ja) 2003-09-08
DE69330523T3 (de) 2010-10-28
FI20041584L (fi) 2004-12-08
ES2338321T3 (es) 2010-05-06
EP0656946B1 (en) 2001-08-01
DK1621554T3 (da) 2009-08-10
CA2142331A1 (en) 1994-03-03
JP3660270B2 (ja) 2005-06-15
EP1621554B2 (en) 2012-08-29
US5874541A (en) 1999-02-23
DE69330523T4 (de) 2012-08-23
JP4414900B2 (ja) 2010-02-10
EP1087013A2 (en) 2001-03-28
ES2322324T3 (es) 2009-06-19
FI950782A0 (fi) 1995-02-20
WO1994004678A1 (en) 1994-03-03
EP0656946B2 (en) 2010-03-31
EP1087013A3 (en) 2001-11-28
ATE420178T1 (de) 2009-01-15
DE69334258D1 (de) 2009-02-26
ES2338791T3 (es) 2010-05-12
US6015695A (en) 2000-01-18
JP2002053600A (ja) 2002-02-19
EP1589107A1 (en) 2005-10-26
EP1498427A1 (en) 2005-01-19
US5840526A (en) 1998-11-24
EP1589107B1 (en) 2009-12-23
EP1621554B1 (en) 2009-04-08
JP2005170953A (ja) 2005-06-30
FI950782A7 (fi) 1995-04-20
FI20070170L (fi) 2007-02-28
ATE452975T1 (de) 2010-01-15
PT1589107E (pt) 2010-03-29
ES2162823T5 (es) 2010-08-09
DE69334308D1 (de) 2010-02-04
FI115462B (fi) 2005-05-13
PT1498427E (pt) 2010-03-22
FI117975B (fi) 2007-05-15
PT1621554E (pt) 2009-07-13
DK1087013T3 (da) 2009-05-11
AU4949793A (en) 1994-03-15
US5800988A (en) 1998-09-01
AU701578B2 (en) 1999-02-04
CA2142331C (en) 2010-02-02
GR3037024T3 (en) 2002-01-31
ATE427968T1 (de) 2009-04-15
ATE452207T1 (de) 2010-01-15
DK1589107T3 (da) 2010-04-26
EP1498427B1 (en) 2009-12-16
DK1498427T3 (da) 2010-04-26
DK1621554T4 (da) 2012-12-17
EP1087013B1 (en) 2009-01-07
PT1087013E (pt) 2009-04-15
US5759808A (en) 1998-06-02
EP0656946A1 (en) 1995-06-14
EP1621554A1 (en) 2006-02-01
DE69330523T2 (de) 2002-03-28
ES2325541T3 (es) 2009-09-08
ATE203767T1 (de) 2001-08-15
FI120404B (fi) 2009-10-15

Similar Documents

Publication Publication Date Title
ES2162823T3 (es) Inmunoglobulinas desprovistas de cadenas ligeras.
NO911217L (no) Lanterne og linse for denne lanterne.
SG55079A1 (en) Multivalent single chain antibodies
HU9603183D0 (en) Interleukin-5 specific recombinant antibodies
AU5647896A (en) Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ZA936086B (en) Immunoglobulins devoid of light chains.
ES1016787Y (es) Dispositivo para la reparacion de eslabones de cadenas.
FR2721378B1 (fr) Couvercle pour boîtier de suspension pour luminaire.
ES1028236Y (es) Colgante de seguridad para lamparas.
ES261234Y (es) Colgante para articulos de iluminacion.
ES1026589Y (es) Dispositivo de doble sujecion para lamparas halogenas.
ES1022104Y (es) Cierre para articulos de joyeria.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 656946

Country of ref document: ES